<SEC-DOCUMENT>0001213900-23-040917.txt : 20230517
<SEC-HEADER>0001213900-23-040917.hdr.sgml : 20230517
<ACCEPTANCE-DATETIME>20230517172140
ACCESSION NUMBER:		0001213900-23-040917
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20230515
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230517
DATE AS OF CHANGE:		20230517

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Modular Medical, Inc.
		CENTRAL INDEX KEY:			0001074871
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				870620495
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41277
		FILM NUMBER:		23932925

	BUSINESS ADDRESS:	
		STREET 1:		16772 WEST BERNARDO DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127
		BUSINESS PHONE:		858-800-3500

	MAIL ADDRESS:	
		STREET 1:		16772 WEST BERNARDO DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BEAR LAKE RECREATION INC
		DATE OF NAME CHANGE:	19981208
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea178793-8k_modular.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:MODD="http://modular-medical.com/20230515">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_MODD_modular%2Dmedical.com_20230515 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20230515_20230515 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001074871 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-05-15to2023-05-15" name="dei:EntityCentralIndexKey">0001074871</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-05-15to2023-05-15" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="modd-20230515.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-05-15to2023-05-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-15</xbrli:startDate>
        <xbrli:endDate>2023-05-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED
STATES<br />
SECURITIES AND EXCHANGE COMMISSION<br />
Washington, D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
<span id="xdx_901_edei--DocumentType_c20230515__20230515_zbVu9mrjeNHd"><ix:nonNumeric contextRef="From2023-05-15to2023-05-15" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT<br />
Pursuant to Section 13 or 15(d) of the<br />
Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): <b><span style="text-decoration: underline"><span id="xdx_90F_edei--DocumentPeriodEndDate_c20230515__20230515_zTBrTclMQn51"><ix:nonNumeric contextRef="From2023-05-15to2023-05-15" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">May 15, 2023</ix:nonNumeric></span></span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityRegistrantName_c20230515__20230515_zcmg2zbdgWxd"><ix:nonNumeric contextRef="From2023-05-15to2023-05-15" name="dei:EntityRegistrantName">MODULAR MEDICAL, INC.</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
    name of registrant as specified in its charter)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20230515__20230515_z9sNDCpSTsfe"><ix:nonNumeric contextRef="From2023-05-15to2023-05-15" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityFileNumber_c20230515__20230515_zVWYJiJ69Px6"><ix:nonNumeric contextRef="From2023-05-15to2023-05-15" name="dei:EntityFileNumber">001-41277</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20230515__20230515_zTMO9IXDKB7f"><ix:nonNumeric contextRef="From2023-05-15to2023-05-15" name="dei:EntityTaxIdentificationNumber">87-0620495</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction<br />
    of incorporation)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File
    Number)</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer<br />
    Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20230515__20230515_zxcLoq2HH9m7"><ix:nonNumeric contextRef="From2023-05-15to2023-05-15" name="dei:EntityAddressAddressLine1">10740 Thornmint Road</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressCityOrTown_c20230515__20230515_ze92TF1PYGmf"><ix:nonNumeric contextRef="From2023-05-15to2023-05-15" name="dei:EntityAddressCityOrTown">San Diego</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressStateOrProvince_c20230515__20230515_znSTrITdV0Fi"><ix:nonNumeric contextRef="From2023-05-15to2023-05-15" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityAddressPostalZipCode_c20230515__20230515_zWjruuipUMJc"><ix:nonNumeric contextRef="From2023-05-15to2023-05-15" name="dei:EntityAddressPostalZipCode">92127</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code: <b><span style="text-decoration: underline">(<span id="xdx_90C_edei--CityAreaCode_c20230515__20230515_zDKfrrcl6Gh3"><ix:nonNumeric contextRef="From2023-05-15to2023-05-15" name="dei:CityAreaCode">858</ix:nonNumeric></span>) <span id="xdx_90D_edei--LocalPhoneNumber_c20230515__20230515_zyWGWOwsdyW4"><ix:nonNumeric contextRef="From2023-05-15to2023-05-15" name="dei:LocalPhoneNumber">800-3500</ix:nonNumeric></span></span></b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name or former address, if changed since last report)</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--WrittenCommunications_c20230515__20230515_zyVfqiNU7clh"><ix:nonNumeric contextRef="From2023-05-15to2023-05-15" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the
    Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--SolicitingMaterial_c20230515__20230515_zZ8LSfLdSpU6"><ix:nonNumeric contextRef="From2023-05-15to2023-05-15" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the
    Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span id="xdx_903_edei--PreCommencementTenderOffer_c20230515__20230515_zcdkOiHSwXxl"><ix:nonNumeric contextRef="From2023-05-15to2023-05-15" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b)
    under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20230515__20230515_zUHhq2Tunp3b"><ix:nonNumeric contextRef="From2023-05-15to2023-05-15" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c)
    under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    symbol(s)</b></span></td>
    <td style="text-align: center; padding-bottom: 1.5pt; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--Security12bTitle_c20230515__20230515_zZANXWcRepqc"><ix:nonNumeric contextRef="From2023-05-15to2023-05-15" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--TradingSymbol_c20230515__20230515_zs2U9NbzfSr"><ix:nonNumeric contextRef="From2023-05-15to2023-05-15" name="dei:TradingSymbol">MODD</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_906_edei--SecurityExchangeName_c20230515__20230515_z2SJK7ETWF6"><ix:nonNumeric contextRef="From2023-05-15to2023-05-15" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-align: right; text-indent: -27.35pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-align: right; text-indent: -27.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_901_edei--EntityEmergingGrowthCompany_c20230515__20230515_zTo33bfXnym9"><ix:nonNumeric contextRef="From2023-05-15to2023-05-15" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 1.01</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Entry into a Material Definitive Agreement.</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2023, Modular Medical, Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;)
with Newbridge Securities Corporation (&#8220;Newbridge&#8221; or the &#8220;Underwriter&#8221;), with respect to the issuance and sale
in a firm commitment underwritten offering (the &#8220;Offering&#8221;) by the Company of units of its securities for aggregate gross
proceeds of $9,400,000. Each unit consists of two shares of common stock of the Company, par value $0.001 per share (the &#8220;Common
Stock&#8221;), and one warrant (the &#8220;Warrants&#8221; and together with the Common Stock, the &#8220;Securities&#8221;) to purchase
one share of Common Stock, at a public offering price of $2.13 per unit.&#160;The Warrants will be immediately separable and exercisable, shall have
a per share exercise price of $1.22, and will expire five years from the date of issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Underwriting Agreement, the Company granted the Underwriter a 30-day option to purchase up to an additional 1,322,534 shares
of Common Stock and an additional 661,267 Warrants to cover over-allotments, if any. Newbridge is acting as the sole book-running manager
of the Offering. The Underwriter will be entitled to a cash fee of 7.0% of the aggregate gross proceeds of the Offering and the reimbursement
of certain out-of-pocket expenses of up to $125,000. In connection with the Offering, the Company agreed to issue to Newbridge warrants
to purchase that number of shares of Common Stock equal to an aggregate of 7% of the total shares sold in the Offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing,
indemnification obligations of the Company and the Underwriter, including for liabilities under the Securities Act of 1933, as amended,
other obligations of the parties and termination provisions. In addition, pursuant to the terms of the Underwriting Agreement and related
&#8220;lock-up&#8221; agreements, the Company, each director and executive officer of the Company, and certain stockholders have agreed
with the Underwriter not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our Common Stock or
securities convertible into Common Stock for a period of 90 days after the date on which a final prospectus relating to the Offering
is filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering is expected to close on May 18, 2023, subject to customary closing conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds to the Company from the Offering, after deducting the Underwriter&#8217;s fees and expenses and the Company&#8217;s estimated
offering expenses, are expected to be approximately $8.3 million. The Company intends to use the net proceeds from the Offering for general
corporate purposes, including working capital, to fund its operations through the approval of its product by the FDA, to develop its
initial sales and marketing infrastructure, to fund additional research and development activities, to develop initial manufacturing
and production capabilities and make related capital expenditures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offering was registered with the Commission pursuant to a Registration Statement on Form S-1, as amended (File No. 333-271413), initially
filed by the Company on April 24, 2023, which became effective on May 15, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrants will be issued pursuant to a warrant agency agreement to be entered into by and between the Company and Colonial Stock Transfer
Company, Inc., as warrant agent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing descriptions of the terms and conditions of the Underwriting Agreement do not purport to be complete and are qualified in their
entirety by the full text of the Underwriting Agreement, a copy of which is hereto as Exhibit 1.1 and which is incorporated herein by
reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
legal opinion and consent of Lucosky Brookman LLP relating to the securities is filed as Exhibit 5.1 to this Current Report on Form 8-K
and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 8.01</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other Events.</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 16, 2023, the Company issued a press release announcing the Offering. A copy of the press release is attached as Exhibit 99.1 hereto
and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits:</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1#</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td><a href="ea178793ex1-1_modular.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting Agreement</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000121390023036733/ea177987ex4-5_modular.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant (incorporated by reference to Exhibit 4.5 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on May 5, 2023)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1074871/000121390023036733/ea177987ex4-6_modular.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Underwriter&#8217;s Warrant (incorporated by reference to Exhibit 4.6 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on May 5, 2023)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><a href="ea178793ex5-1_modular.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Lucosky Brookman LLP</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea178793ex99-1_modular.htm">Press Release dated May 16, 2023</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the
    Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedules
and/or exhibits have been omitted from this exhibit pursuant to Item 601(a)(5) of Regulation S-K. The registrant agrees to furnish supplementally
a copy of any omitted schedule or exhibit to the Securities and Exchange Commission upon request.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MODULAR
    MEDICAL, INC.</b></span></td></tr>
  <tr>
    <td style="white-space: nowrap; text-align: justify; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 17, 2023</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    James E. Besser</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    E. Besser</span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2Wmo1ivAyKYksRCK6XXKMJd2R2e3vkXrLViUaBobhnO8cIUKR0UY3yHBelTkcse0a5RBKrJHRXNA70u0uAX9LvGrrWBk3vD8wJc+gZ+aTaKm8MFgf2mKVgJxPo8U0noFcJjMJxV4EvZ6SqXWFxmnVgDIVFEwda3SK32PCUb3IUPseqk7IVpNJIJrIUf5ALKMYDvRQT+KbhTxPRRAOE4iM6d71NXfrqIV1g63vsiP63+ALHQFJUQ== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ea178793ex1-1_modular.htm
<DESCRIPTION>UNDERWRITING AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I>Execution Version</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDERWRITING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>between</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>MODULAR
MEDICAL, inC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>NEWBRIDGE
SECURITIES CORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">May 15, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Newbridge Securities Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1200 North Federal Highway, Suite 400</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boca Raton, Florida 33432</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned, Modular Medical,
Inc., a corporation formed under the laws of the State of Nevada (the &ldquo;<B>Company</B>&rdquo;), hereby confirms its agreement (this
&ldquo;<B>Agreement</B>&rdquo;) with Newbridge Securities Corporation (hereinafter referred to as &ldquo;<B>you</B>&rdquo; or the &ldquo;<B>Underwriter</B>&rdquo;)
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-weight: normal">1.</FONT> <FONT STYLE="font-weight: normal"><U>Purchase and Sale of Shares</U>.</FONT></P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">1.1
<U>Firm Units</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-weight: normal">1.1.1.
<U>Nature and Purchase of Firm Units</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(i)<FONT STYLE="font-size: 10pt">
On the basis of the representations and warranties herein contained, but subject to the terms and conditions herein set forth, the Company
agrees to issue and sell to the Underwriter an aggregate of 4,408,450 units (the &ldquo;</FONT></FONT><FONT STYLE="font-size: 10pt">Firm
Units<FONT STYLE="font-weight: normal">&rdquo;) consisting of (A) an aggregate of 8,816,900 shares (the &ldquo;</FONT>Firm Shares<FONT STYLE="font-weight: normal">&rdquo;)
of the Company&rsquo;s common stock, par value $0.001 per share (&ldquo;</FONT>Common Stock<FONT STYLE="font-weight: normal">&rdquo;),
and (B) warrants exercisable to purchase an aggregate of 4,408,450 shares of Common Stock, in the form attached hereto as <U>Exhibit A</U>
(the &ldquo;</FONT>Warrants<FONT STYLE="font-weight: normal">&rdquo;), which Warrants will have an exercise price of $1.22 per share,
subject to adjustment as provided for therein (the &ldquo;</FONT>Firm Warrants<FONT STYLE="font-weight: normal">&rdquo;). Each individual
Firm Unit shall consist of: (i) two (2) Firm Shares and (ii) one (1) Firm Warrant to purchase one (1) share of Common Stock, which shall
be immediately separable upon issuance. The Firm Shares and the Common Stock issuable upon the exercise of the Warrants (the &ldquo;</FONT>Warrant
Shares<FONT STYLE="font-weight: normal">&rdquo;) consist of authorized but unissued shares of Common Stock to be issued and sold by the
Company.</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(ii)<FONT STYLE="font-size: 10pt">
The Underwriter agrees to purchase from the Company the Firm Units at a purchase price of $1.98 per Firm Unit (with $0.01 allocated to
the value of a full Warrant to purchase one share of common Stock). The Firm Units are to be offered to the public (the &ldquo;</FONT></FONT><FONT STYLE="font-size: 10pt">Offering<FONT STYLE="font-weight: normal">&rdquo;)
at the offering price set forth on the cover page of the Prospectus (as defined in <U>Section 2.1.1</U>).</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-weight: normal">1.1.2.
<U>Firm Units Payment and Delivery.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(i)
<FONT STYLE="font-size: 10pt">Delivery and payment for the Firm Units shall be made at 10:00 a.m., Eastern time, on May 18, 2023 or at
such earlier time as shall be agreed upon by the Underwriter and the Company, at the offices of McGuireWoods LLP, 1251 Avenue of the
Americas, 20<SUP>th</SUP> Floor, New York, New York 10020 </FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(&ldquo;<B>Underwriter&rsquo;s
Counsel</B>&rdquo;)<B>,</B></FONT> <FONT STYLE="font-size: 10pt; font-weight: normal">or at such other place (or remotely by electronic
transmission) as shall be agreed upon in writing by the Underwriter and the Company. The hour and date of delivery and payment for the
Firm Units is called the &ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Closing Date.</B></FONT><FONT STYLE="font-weight: normal">&rdquo;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">(ii)<FONT STYLE="font-size: 10pt">
Payment for the Firm Units shall be made on the Closing Date by wire transfer in Federal (same day) funds, payable to the order of the
Company upon delivery of the certificates (in form and substance satisfactory to the Underwriter) representing the Firm Shares and the
Firm Warrants (or through the facilities of The Depository Trust Company (&ldquo;</FONT></FONT><FONT STYLE="font-size: 10pt">DTC<FONT STYLE="font-weight: normal">&rdquo;))
for the account of the Underwriter. The Firm Shares and the Firm Warrants shall each be registered in such name or names and in such authorized
denominations as the Underwriter may request in writing at least two (2) Business Days prior to the Closing Date. The Company shall not
be obligated to sell or deliver the Firm Units except upon tender of payment by the Underwriter for all of the Firm Units. The term &ldquo;</FONT>Business
Day<FONT STYLE="font-weight: normal">&rdquo; means any day other than a Saturday, a Sunday or a legal holiday or a day on which banking
institutions are authorized or obligated by law to close in New York, New York.</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">1.2
<U>Over-allotment Option</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.2.1.
<U>Option Shares</U>. The Company hereby grants to the Underwriter an option (the &ldquo;</FONT>Over-allotment Option<FONT STYLE="font-weight: normal">&rdquo;)
to purchase from the Company (i) up to an additional 1,322,534 shares of Common Stock, representing up to 15% of the Firm Shares sold
in the Offering (the &ldquo;</FONT>Option Shares<FONT STYLE="font-weight: normal">&rdquo;), and (ii) additional Warrants to purchase up
to 661,267 shares of Common Stock, representing up to fifteen percent (15%) of the Firm Warrants sold in the Offering (the &ldquo;</FONT>Option
Warrants<FONT STYLE="font-weight: normal">,&rdquo; and together with the Option Shares, the &ldquo;</FONT>Option Securities<FONT STYLE="font-weight: normal">&rdquo;),
for the purpose of covering over-allotments of such securities, if any. The purchase price to be paid for the Option Shares and/or Option
Warrants will be the price set forth in <U>Section 1.1.1</U> for such securities. The Over-allotment Option may be elected with respect
to, at the Underwriter&rsquo;s sole discretion, Option Shares and Option Warrants together, solely Option Shares, solely Option Warrants,
or any combination thereof. The Firm Shares, the Firm Warrants, the Option Shares, the Option Warrants and the Warrant Shares are hereinafter
referred to collectively as the &ldquo;</FONT>Public Securities<FONT STYLE="font-weight: normal">.&rdquo;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.2.2.
<U>Exercise of the Option</U>. The Over-allotment Option granted pursuant to <U>Section 1.2.1</U> may be exercised by the Underwriter
as to all (at any time) or any part (from time to time) of the Option Shares and/or Option Warrants within 30 days after the date hereof.
The Underwriter shall not be under any obligation to purchase any Option Securities prior to the exercise of the Over-allotment Option.
The Over-allotment Option granted hereby shall be exercised by the giving of electronic notice to the Company from the Underwriter, which
shall be confirmed in writing by overnight mail or facsimile or other electronic transmission, setting forth the number of Option Securities
to be purchased and the date and time for delivery of and payment for the Option Securities (the &ldquo;</FONT>Option Closing Date<FONT STYLE="font-weight: normal">&rdquo;),
which shall not be later than five (5) full Business Days after the date of the notice or such other time as shall be agreed upon by the
Company and the Underwriter, at the offices of Underwriter&rsquo;s Counsel or at such other place (including remotely by electronic transmission)
as shall be agreed upon by the Company and the Underwriter. If such delivery and payment for the Option Securities does not occur on the
Closing Date, the applicable Option Closing Date will be as set forth in the notice. Upon exercise of the Over-allotment Option with respect
to all or any portion of the Option Securities, subject to the terms and conditions set forth herein, the Company shall become obligated
to sell to the Underwriter the number of Option Shares and/or Option Warrants specified in such notice.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.2.3. <U>Payment
and Delivery</U>. Payment for the Option Securities shall be made on each Option Closing Date by wire transfer in Federal (same day)
funds, payable to the order of the Company upon delivery to you of certificates (in form and substance satisfactory to the
Underwriter) representing the Option Shares and/or Option Warrants (or through the facilities of DTC) for the account of the
Underwriter. The Option Securities shall be registered in such name or names and in such authorized denominations as the Underwriter
may request in writing at least two (2) Business Days prior to each Option Closing Date. </FONT>The Company shall not be obligated
to sell or deliver the <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Option Shares
and/or Option Warrants except upon tender of payment by the Underwriter for applicable Option Securities. An Option Closing Date may
be simultaneous with, but not earlier than, the Closing Date; and in the event that such time and date are simultaneous with the
Closing Date, the term &ldquo;Closing Date&rdquo; shall refer to the time and date of delivery of the Firm Units and Option
Securities.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">1.3
<U>Underwriter Warrants</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.3.1.
<U>Purchase Warrants</U>. The Company hereby agrees to issue to the Underwriter (and/or its affiliates, employees or third-party designees)
on the Closing Date and each Option Closing Date, if any, an option (&ldquo;</FONT>Underwriter&rsquo;s Warrant<FONT STYLE="font-weight: normal">&rdquo;)
for the purchase of an aggregate of a number of shares of Common Stock, representing 7% of the Firm Shares sold on the Closing Date and
7% of the Option Shares sold each Option Closing Date, if any. The Underwriter&rsquo;s Warrant, in the form attached hereto as <U>Exhibit
C</U>, shall be exercisable, in whole or in part, commencing on the date that is 180 days after the Effective Date and expiring on the
four-year anniversary of the Effective Date at an initial exercise price per share of Common Stock of $1.325, which is equal to 125% of
the public offering price of the Firm Units. The Underwriter&rsquo;s Warrant and the shares of Common Stock issuable upon exercise thereof
are hereinafter referred to together as the &ldquo;</FONT>Underwriter&rsquo;s Securities<FONT STYLE="font-weight: normal">.&rdquo; The
Underwriter understands and agrees that there are significant restrictions pursuant to FINRA Rule 5110 against transferring the Underwriter&rsquo;s
Warrant and the underlying shares of Common Stock during the one hundred eighty (180) days after the Effective Date and by its acceptance
thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Underwriter&rsquo;s Warrant, or any portion thereof,
or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition
of such securities for a period of one hundred eighty (180) days following the Effective Date to anyone other than (i) an Underwriter
or a selected dealer in connection with the Offering or (ii) a bona fide officer, partner, employee or registered representative of the
Underwriter or selected dealer; and only if any such transferee agrees to the foregoing lock-up restrictions.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.3.2.
<U>Delivery</U>. Delivery of the Underwriter&rsquo;s Warrant shall be made on the Closing Date and each Option Closing Date, if any, and
shall be issued in the name or names and in such authorized denominations as the Underwriter may request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">2.
<U>Representations and Warranties of the Company</U>. The Company represents and warrants to the Underwriter as of the Applicable Time
(as defined below), as of the Closing Date and as of each Option Closing Date, if any, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.1
<U>Filing of Registration Statement</U></FONT><FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.1.1.
The Company has prepared and filed with the U.S. Securities and Exchange Commission (the &ldquo;</FONT>Commission<FONT STYLE="font-weight: normal">&rdquo;)
a registration statement on Form S-1, including a prospectus, for the registration under the Securities Act of 1933, as amended (the
&ldquo;</FONT>Securities Act<FONT STYLE="font-weight: normal">&rdquo;) of the offering and sale of the Public Securities and the Underwriter&rsquo;s
Securities, including each of the exhibits, financial statements and schedules thereto, including any material incorporated by reference
therein, which registration statement was prepared by the Company in all material respects in conformity with the requirements of the
Securities Act and the rules and regulations of the Commission under the Securities Act (the &ldquo;</FONT>Securities Act Regulations<FONT STYLE="font-weight: normal">&rdquo;)
and contains or will contain all material statements that are required to be stated therein in accordance with the Securities Act and
the Securities Act Regulations. Except as the context may otherwise require, such registration statement on file with the Commission
at any given time, including (i) any amendments thereto to such time, exhibits and schedules thereto at such time, documents filed as
a part thereof or incorporated pursuant to Item 12 of Form S-1 under the Securities Act at such time and the documents and information
otherwise deemed to be a part thereof or included therein pursuant to Rule 430A of the Securities Act Regulations (the &ldquo;</FONT>Rule
430A Information<FONT STYLE="font-weight: normal">&rdquo;) or otherwise pursuant to the <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">Securities
Act Regulations at such time, is referred to herein as the &ldquo;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
Statement<FONT STYLE="font-weight: normal">.&rdquo; If the Company files any registration statement pursuant to Rule 462(b) of the Securities
Act Regulations, then after such filing, the term &ldquo;Registration Statement&rdquo; shall include such registration statement filed
pursuant to Rule 462(b). </FONT>&ldquo;Preliminary Prospectus<I>&rdquo;</I> <FONT STYLE="font-weight: normal">means any preliminary prospectus,
including any material incorporated by reference therein, included in the Registration Statement prior to the time at which the Commission
declared the Registration Statement effective. &ldquo;</FONT>Prospectus<FONT STYLE="font-weight: normal">&rdquo; means the prospectus
that discloses the public offering price and other final terms of the Securities and the offering and otherwise satisfies Section 10(a)
of the Securities Act. All references in this Agreement to the Registration Statement, the Preliminary Prospectus, the Prospectus or
any amendment or supplement to any of the foregoing, is deemed to include the copy filed with the Commission pursuant to its Electronic
Data Gathering, Analysis and Retrieval System or any successor system thereto (&ldquo;</FONT>EDGAR<FONT STYLE="font-weight: normal">&rdquo;).</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<B>Applicable Time</B>&rdquo;
means 5:00 p.m., Eastern time, on the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<B>Disclosure Package</B>&rdquo;
means any Issuer General Use Free Writing Prospectus issued at or prior to the Applicable Time, the Preliminary Prospectus dated May 12,
2023 and the information included on <U>Schedule 1-A</U> hereto, all considered together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<B>Effective Date</B>&rdquo;
means the date that the Registration Statement became effective under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<B>Issuer Free Writing
Prospectus</B>&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433 of the Securities Act Regulations
(&ldquo;<B>Rule 433</B>&rdquo;), including without limitation any &ldquo;free writing prospectus&rdquo; (as defined in Rule 405 of the
Securities Act Regulations) relating to the Public Securities that is (i) required to be filed with the Commission by the Company, (ii)
a &ldquo;road show that is a written communication&rdquo; within the meaning of Rule 433(d)(8)(i), whether or not required to be filed
with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of
the Public Securities or of the Offering that does not reflect the final terms, in each case in the form filed or required to be filed
with the Commission or, if not required to be filed, in the form retained in the Company&rsquo;s records pursuant to Rule 433(g).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<B>Issuer General Use
Free Writing Prospectus</B>&rdquo; means any Issuer Free Writing Prospectus that is intended for general distribution to prospective investors
(other than a &ldquo;<I>bona fide</I> electronic road show,&rdquo; as defined in Rule 433), as evidenced by its being specified in <U>Schedule
1-B</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<B>Issuer Limited Use
Free Writing Prospectus</B>&rdquo; means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.1.2.
<U>Pursuant to the Exchange Act.</U> The Common Stock is registered pursuant to Section 12(b) under the Securities Exchange Act of 1934,
as amended (the &ldquo;</FONT>Exchange Act<FONT STYLE="font-weight: normal">&rdquo;). The Company has taken no action designed to, or
likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act, nor has the Company received any
notification that the Commission is contemplating terminating such registration.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.2
<U>Stock Exchange Listing.</U> The Common Stock is listed on The Nasdaq Capital Market (the &ldquo;</FONT><FONT STYLE="font-style: normal">NasdaqCM<FONT STYLE="font-weight: normal">&rdquo;),
and the Company has taken no action designed to, or likely to have the effect of, delisting the Common Stock from the NasdaqCM, nor has
the Company received any notification that the NasdaqCM is contemplating terminating such listing, except as described in the Registration
Statement, the Disclosure Package and the Prospectus.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.3
<U>No Stop Orders, etc</U>. Neither the Commission nor any state regulatory authority has issued any order preventing or suspending the
use of the Registration Statement, any Preliminary Prospectus or <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Prospectus or has instituted or, to the Company&rsquo;s knowledge, threatened to institute, any proceedings with respect to such an order.
The Company has complied with each request (if any) from the Commission for additional information.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.4
<U>Disclosures in Registration Statement</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.1.
<U>Compliance with Securities Act; 10b-5 Representation</U>. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(i)<FONT STYLE="font-size: 10pt">
Each of the Registration Statement and any post-effective amendment thereto, at the time it became effective, at the date of this Agreement
and at the Closing Date and each Option Closing Date, complied and will comply in all material respects with the requirements of the Securities
Act and the Securities Act Regulations. Each Preliminary Prospectus and the Prospectus, at the time each was filed or will be filed with
the Commission, at the date of this Agreement and at the Closing Date and each Option Closing Date, complied or will comply in all material
respects with the requirements of the Securities Act and the Securities Act Regulations. The Preliminary Prospectus delivered to the Underwriter
for use in connection with this Offering and the Prospectus was or will be identical to the electronically transmitted copies thereof
filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(ii)<FONT STYLE="font-size: 10pt">
Neither the Registration Statement nor any amendment thereto, at its Effective Date, as of the Applicable Time, or at the Closing Date
or any Option Closing Date contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to
state a material fact required to be stated therein or necessary to make the statements therein not misleading.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(iii)<FONT STYLE="font-size: 10pt">
The Disclosure Package, as of the Applicable Time, as of the date of this Agreement, at the Closing Date or at any Option Closing Date
did not, does not and will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading; and each Issuer Limited Use Free
Writing Prospectus hereto does not conflict with the information contained in the Registration Statement, the Preliminary Prospectus or
the Prospectus, and each such Issuer Limited Use Free Writing Prospectus, as supplemented by and taken together with the Prospectus as
of the Applicable Time, did not include an untrue statement of a material fact or omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading; <I><U>provided</U></I>, <I><U>however</U></I>,
that this representation and warranty shall not apply to statements made or statements omitted in reliance upon and in conformity with
written information furnished to the Company with respect to the Underwriter by the Underwriter expressly for use in the Registration
Statement, the Disclosure Package or the Prospectus or any amendment thereof or supplement thereto. The parties acknowledge and agree
that such information provided by or on behalf of the Underwriter consists solely of the following disclosure contained in the &ldquo;Underwriting&rdquo;
section of the Prospectus: the third full paragraph under the heading &ldquo;Underwriting,&rdquo; the statements under the subheading
titled &ldquo;Price Stabilization, Short Positions and Penalty Bids&rdquo; and the statements under the subheading titled &ldquo;Electronic
Distribution&rdquo; (collectively, the &ldquo;</FONT></FONT><FONT STYLE="font-size: 10pt">Underwriter&rsquo;s Information<FONT STYLE="font-weight: normal">&rdquo;);
and</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(iv)<FONT STYLE="font-size: 10pt">
Neither the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of
any filing with the Commission pursuant to Rule 424(b) or at the Closing Date or any Option Closing Date, included, includes or will include
an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading; <I>provided</I>, <I>however</I>, that this representation
and warranty shall not apply to the&nbsp;Underwriter&rsquo;s Information.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.2.
<U>Disclosure of Agreements</U>. The agreements and documents described in the Registration Statement, the Disclosure Package and the
Prospectus conform in all material respects to the descriptions thereof contained therein, and there are no agreements or other documents
required by the Securities Act, the Securities Act Regulations or the Exchange Act to be described in the Registration Statement, the
Disclosure Package and the Prospectus or to be filed with the Commission as exhibits to the Registration Statement, that have not been
so described or filed. Each agreement or other instrument (however characterized or described) to which the Company or the Subsidiary
is a party or by which it is or may be bound or affected and (i)&nbsp;that is referred to or incorporated by reference in the Registration
Statement, the Disclosure Package or the Prospectus, or (ii)&nbsp;is material to the Company&rsquo;s business, has been duly authorized
and validly executed by the Company, is in full force and effect in all material respects and is enforceable against the Company and,
to the Company&rsquo;s knowledge, the other parties thereto, in accordance with its terms, except (x)&nbsp;as such enforceability may
be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally, (y)&nbsp;as enforceability
of any indemnification or contribution provision may be limited under the federal or state securities laws, and (z)&nbsp;that the remedy
of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion
of the court before which any proceeding therefor may be brought. None of such agreements or instruments has been assigned by the Company,
and neither the Company nor, to the Company&rsquo;s knowledge, any other party is in default thereunder and, to the Company&rsquo;s knowledge,
no event has occurred that, with the lapse of time or the giving of notice, or both, would constitute a default thereunder. Performance
by the Company of the material provisions of such agreements or instruments will not result in a material violation of any existing applicable
law, rule, regulation, judgment, order or decree of any governmental or regulatory agency, body or court, domestic or foreign, having
jurisdiction over the Company or any of its assets or business (each, a &ldquo;</FONT>Governmental Entity<FONT STYLE="font-weight: normal">&rdquo;),
including, without limitation, those relating to environmental laws and regulations.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.3.
<U>Prior Securities Transactions</U>. Since January 1, 2021, no securities of the Company have been sold by the Company or by or on behalf
of, or for the benefit of, any person or persons controlling, controlled by or under common control with the Company, except as disclosed
in the Registration Statement, the Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.4.
<U>Regulations</U>. The disclosures in the Registration Statement, the Disclosure Package and the Prospectus concerning the effects of
federal, state, local and all foreign laws, rules and regulations relating to the Company&rsquo;s business as currently conducted or contemplated
to be conducted are correct and complete in all material respects and no other such laws, rules or regulations are required to be disclosed
in the Registration Statement, the Disclosure Package and the Prospectus that are not so disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.5.
<U>No Other Distribution of Offering Materials.</U> The Company has not, directly or indirectly, distributed and will not distribute any
offering material in connection with the Offering other than any Preliminary Prospectus, the Disclosure Package, the Prospectus and other
materials, if any, permitted under the Securities Act and consistent with <U>Section 3.2</U> below. The Company is not an &ldquo;ineligible
issuer&rdquo; in connection with the Offering pursuant to Rules 164, 405 and 433 under the Securities Act. The Company will file with
the Commission all Issuer Free General Use Writing Prospectuses and all Issuer Limited Use Free Writing Prospectuses (other than a &ldquo;road
show&rdquo; as defined in Rule 433(d) of the Securities Act Regulations, if any) in the time and manner required under Rule 433(d) of
the Securities Act Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.5
<U>Changes After Dates in Registration Statement</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.5.1.
<U>No Material Adverse Change</U>. Since the respective dates as of which information is given in the Registration Statement, the Disclosure
Package and the Prospectus, except as otherwise specifically stated therein: (i)&nbsp;there has been no material adverse change in the
financial position or results of operations of the Company and the Subsidiary, nor any change or development that, singularly or in the
aggregate, would involve a material adverse change or a prospective material adverse change, in or affecting the condition (financial
or otherwise), results of operations, business, assets<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, properties
or prospects of the Company and the Subsidiary, taken as a whole (a &ldquo;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Material
Adverse Change</B><FONT STYLE="font-weight: normal">&rdquo;); (ii)&nbsp;there have been no material transactions entered into by the
Company, other than as contemplated pursuant to this Agreement; and (iii)&nbsp;no officer or director of the Company or the Subsidiary
has resigned from any position with the Company or such Subsidiary.</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.5.2.
<U>Recent Securities Transactions, etc</U>. Subsequent to the respective dates as of which information is given in the Registration Statement,
the Disclosure Package and the Prospectus, and except as may otherwise be indicated or contemplated herein or disclosed in the Registration
Statement, the Disclosure Package and the Prospectus, the Company has not: (i)&nbsp;issued any securities or incurred any liability or
obligation, direct or contingent, for borrowed money; or (ii)&nbsp;declared or paid any dividend or made any other distribution on or
in respect to its capital stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.6 <U>Disclosures
in Commission Filings</U>. Since January 1, 2020, (i) none of the Company&rsquo;s filings with the Commission contained any untrue
statement of a material fact or omitted to state any material fact necessary in order to make the statements therein, in light of
the circumstances under which they were made, not misleading; and (ii) the Company has made all filings with the Commission required
under the Exchange Act and the rules and regulations of the Commission promulgated thereunder (the &ldquo;</FONT><FONT STYLE="font-style: normal">Exchange
Act Regulations<FONT STYLE="font-weight: normal">&rdquo;).</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.7
<U>Independent Accountants</U>. To the Company&rsquo;s knowledge, Farber Hass Hurley LLP (the &ldquo;</FONT><FONT STYLE="font-style: normal">Auditor<FONT STYLE="font-weight: normal">&rdquo;),
whose report is filed with the Commission as part of the Registration Statement, the Disclosure Package and the Prospectus, is an independent
registered public accounting firm as required by the Securities Act and the Securities Act Regulations and the Public Company Accounting
Oversight Board. The Auditor has not, during the periods covered by the financial statements included in or incorporated by reference
in the Registration Statement, the Disclosure Package and the Prospectus, provided to the Company any prohibited non-audit services, as
such term is used in Section 10A(g) of the Exchange Act.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.8
<U>Financial Statements, etc</U>. The financial statements, including the notes thereto and supporting schedules, included or incorporated
by reference in the Registration Statement, the Disclosure Package and the Prospectus, fairly present the financial position and the
results of operations of the Company at the dates and for the periods to which they apply; and such financial statements have been prepared
in conformity with U.S. generally accepted accounting principles (&ldquo;</FONT><FONT STYLE="font-style: normal">GAAP<FONT STYLE="font-weight: normal">&rdquo;),
consistently applied throughout the periods involved (provided that unaudited interim financial statements are subject to year-end audit
adjustments that are not expected to be material in the aggregate and do not contain all footnotes required by GAAP); and the supporting
schedules, if any, included in the Registration Statement, the Disclosure Package and the Prospectus present fairly the information required
to be stated therein. Except as included therein, no historical or pro forma financial statements are required to be included or incorporated
by reference in the Registration Statement, the Disclosure Package or the Prospectus under the Securities Act or the Securities Act Regulations.
All disclosures contained in the Registration Statement, the Disclosure Package or the Prospectus regarding &ldquo;non-GAAP financial
measures&rdquo; (as such term is defined by the rules and regulations of the Commission), if any, comply with Regulation G of the Exchange
Act and Item 10 of Regulation S-K of the Securities Act, to the extent applicable. Each of the Registration Statement, the Disclosure
Package and the Prospectus discloses all material off-balance sheet transactions, arrangements, obligations (including contingent obligations),
and other relationships of the Co<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mpany with unconsolidated
entities or other persons required to be disclosed under Instruction 8 to Item 303(b) of Regulation S-K that may have a material current
or future effect on the Company&rsquo;s financial condition, changes in financial condition, results of operations, liquidity, capital
expenditures, capital resources, or significant components of revenues or expenses. Except as disclosed or incorporated by reference
in the Registration Statement, the Disclosure Package and the Prospectus, (a) the Company has not incurred any material liabilities or
obligations, direct or contingent, or entered into any material </FONT>transactions other than in the ordinary course of business, (b) the
Company has not declared or paid any dividends or made any distribution of any kind with respect to its capital stock, (c) there has not
been any change in the capital stock of the Company, (d) other than in the ordinary course of business and consistent with the Company&rsquo;s
prior policies, made any grants under any stock compensation plan, and (e) there has not been any material adverse change in the Company&rsquo;s
long-term or short-term debt.</font></font>
<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">2.9
<U>Authorized Capital; Options, etc</U>. The Company had, at th</FONT><FONT STYLE="font-style: normal; font-weight: normal">e date or
dates indicated in the Registration Statement, the Disclosure Package and the Prospectus, the duly authorized, issued and outstanding
capitalization as set forth therein. Based on the assumptions stated in the Registration Statement, the Disclosure Package and the Prospectus,
the Company will have on the Closing Date and each Option Closing Date, if any, the adjusted stock capitalization set forth therein.
Except as set forth in, or contemplated by, the Registration Statement, the Disclosure Package, the Prospectus, on the Effective Date,
as of the Applicable Time and on the Closing Date and any Option Closing Date, there will be no stock options, warrants, or other rights
to purchase or otherwise acquire any authorized, but unissued shares of Common Stock or any security convertible or exercisable into
shares of Common Stock, or any contracts or commitments to issue or sell shares of Common Stock or any such options, warrants, rights
or convertible securities.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.10
<U>Valid Issuance of Securities, etc.</U></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.10.1.
<U>Outstanding Securities</U>. All issued and outstanding securities of the Company issued prior to the transactions contemplated by this
Agreement have been duly authorized and validly issued and are fully paid and non-assessable; the holders thereof have no rights of rescission
or the ability to force the Company to repurchase such securities with respect thereto, and are not subject to personal liability by reason
of being such holders; and none of such securities were issued in violation of the preemptive rights, rights of first refusal or rights
of participation of any holders of any security of the Company or similar contractual rights granted by the Company. The authorized shares
of Common Stock conform in all material respects to all statements relating thereto contained in the Registration Statement, the Disclosure
Package and the Prospectus. The offers and sales of the outstanding shares of Common Stock, options, warrants and other rights to purchase
or exchange such securities for shares of Common Stock were at all relevant times either registered under the Securities Act and the applicable
state securities or &ldquo;blue sky&rdquo; laws or, based in part on the representations and warranties of the purchasers of such shares
of Common Stock, exempt from such registration requirements. The description of the Company&rsquo;s stock option, stock bonus and other
stock plans or arrangements, and the options or other rights granted thereunder, as described in the Registration Statement, the Disclosure
Package and the Prospectus, accurately and fairly present, in all material respects, the information required to be shown with respect
to such plans, arrangements, options and rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.10.2. <U>Securities
Sold Pursuant to this Agreement</U>. The Firm Shares and the Option Shares have been duly authorized for issuance and sale and, when
issued and paid for, will be validly issued, fully paid and non-assessable; the holders thereof are not and will not be subject to
personal liability by reason of being such holders; the Public Securities and the Underwriter&rsquo;s Securities are not and will
not be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the
Company; and all corporate action required to be taken for the authorization, issuance and sale of the Public Securities and the
Underwriter&rsquo;s Securities has been duly and validly taken. The Public Securities and the Underwriter&rsquo;s Securities conform
in all material respects to all statements with respect thereto contained in the Registration Statement, the Disclosure Package and
the Prospectus. All corporate action required to be taken for the authorization, issuance and sale of the Warrants and the
Underwriter&rsquo;s Warrant has been duly and validly taken; the shares of Common Stock issuable upon exercise of the Warrants and
the Underwriter&rsquo;s Warrant have been duly authorized and reserved for issuance by all necessary corporate action on the part of
the Company and when paid for and issued upon exercise in accordance with the Warrants and the Underwriter&rsquo;s Warrant,
respectively, such shares of Common Stock </FONT>will be validly issued, fully paid and non-assessable; the holders thereof will not
be subject to personal liability by reason of being such holders; and such shares of Common Stock will not be subject to the
preemptive rights of any holders of any security of the Company or similar contractual rights granted by the Company.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.11
<U>Registration Rights of Third Parties</U>. Except as set forth in the Registration Statement, the Disclosure Package and the Prospectus,
no holders of any securities of the Company or any options, warrants, rights or other securities exercisable for or convertible or exchangeable
into securities of the Company have the right to require the Company to register the sale or resale of any such securities of the Company
under the Securities Act or to include any such securities in the Registration Statement or any other registration statement to be filed
by the Company.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.12
<U>Validity and Binding Effect of Agreement</U>. The execution, delivery and performance of this Agreement, the Warrants, the Underwriter&rsquo;s
Warrant and the Warrant Agency Agreement between the Company and the Company&rsquo;s transfer agent (the &ldquo;</FONT><FONT STYLE="font-style: normal">Warrant
Agency Agreement<FONT STYLE="font-weight: normal">&rdquo;) have been duly and validly authorized by the Company, and, when executed and
delivered, will constitute valid and binding agreements of the Company, enforceable against the Company in accordance with their respective
terms, except: (i)&nbsp;as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo;
rights generally; (ii)&nbsp;as enforceability of any indemnification or contribution provision may be limited under the federal or state
securities laws; and (iii)&nbsp;that the remedy of specific performance and injunctive and other forms of equitable relief may be subject
to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.13
<U>No Conflicts, etc</U>. The execution, delivery and performance by the Company of this Agreement, the Warrant Agency Agreement, the
Warrants and the Underwriter&rsquo;s Warrant and all ancillary documents, the consummation by the Company of the transactions herein and
therein contemplated and the compliance by the Company with the terms hereof and thereof do not and will not, with or without the giving
of notice or the lapse of time or both: (i)&nbsp;result in a material breach of, or conflict with any of the terms and provisions of,
or constitute a material default under, or result in the creation, modification, termination or imposition of any lien, charge or encumbrance
upon any property or assets of the Company or the Subsidiary pursuant to the terms of any indenture, mortgage, deed of trust, loan agreement
or any other agreement or instrument to which the Company or the Subsidiary is a party or as to which any property of the Company or the
Subsidiary is a party; (ii)&nbsp;result in any violation of the provisions of the Company&rsquo;s certificate of incorporation (as the
same may be amended or restated from time to time, the &ldquo;</FONT><FONT STYLE="font-style: normal">Charter<FONT STYLE="font-weight: normal">&rdquo;)
or the Company&rsquo;s bylaws (as the same may be amended or restated from time to time, the &ldquo;</FONT>Bylaws<FONT STYLE="font-weight: normal">&rdquo;);
or (iii)&nbsp;violate any existing applicable law, rule, regulation, judgment, order or decree of any Governmental Entity as of the date
hereof, except in the case of clauses <U>(i)</U> or <U>(iii)</U>, as would not result in a Material Adverse Change.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.14
<U>No Defaults; Violations</U>. No material default exists, and no event has occurred that, with the lapse of time or the giving of notice,
or both, would constitute a default, in the due performance and observance of any term, covenant or condition of any material license,
contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement or instrument evidencing an obligation
for borrowed money, or any other material agreement or instrument to which the Company or the Subsidiary is a party or by which the Company
or the Subsidiary may be bound or to which any of the properties or assets of the Company or the Subsidiary is subject. Neither the Company
nor the Subsidiary is (i) in violation of any term or provision of its Charter or Bylaws, or (ii) in violation of any franchise, license,
permit, applicable law, rule, regulation, judgment or decree of any Governmental Entity, except in the case of clause <U>(ii)</U>, such
as would not result in a Material Adverse Change.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.15
<U>Corporate Power; Licenses</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.15.1.
<U>Corporate Power</U>. The Company has all requisite corporate power and authority, as of the date hereof, the Applicable Time, the Closing
Date and any Option Closing Date, to conduct its business as described in the Registration Statement, the Disclosure Package and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.15.2.
<U>Licenses</U>. The Company (A) possesses the licenses, permits, certificates, authorizations, consents and approvals (collectively,
&ldquo;</FONT>Authorizations<FONT STYLE="font-weight: normal">&rdquo;) issued by the appropriate Governmental Entities necessary to conduct
its business as currently conducted as described in the Registration Statement, the Disclosure Package and the Prospectus, and (B) has
obtained all necessary Authorizations from other persons necessary to conduct its business, except, in each case of <U>clauses (A)</U>
and <U>(B)</U>, (i) as described in the Registration Statement, the Disclosure Package or the Prospectus or (ii) to the extent that any
failure to possess any Authorizations, provide any notice, make any filing, or obtain any Authorizations would not, individually or in
the aggregate, reasonably be expected to result in a Material Adverse Change. Neither the Company nor the Subsidiary is in violation of,
or in default under, any Authorizations, except as would not reasonably be expected to result in a Material Adverse Change. All of the
Authorizations are valid and in full force and effect, except when the invalidity of such Authorizations or the failure of such Authorizations
to be in full force and effect would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Change.
The Company has not received any notice of proceedings relating to the revocation or modification of any Authorization which, individually
or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Change.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.15.3.
<U>Transactions Contemplated Herein</U>. The Company has all corporate power and authority to enter into this Agreement, the Warrant Agency
Agreement, the Warrants and the Underwriter&rsquo;s Warrant and to carry out the provisions and conditions hereof, and all Authorizations
required in connection therewith have been obtained. No authorization of, and no filing with, any Governmental Entity is required for
the valid issuance, sale and delivery of the Public Securities and the Underwriter&rsquo;s Securities and the consummation of the transactions
and agreements contemplated by this Agreement, the Warrant Agency Agreement and the Warrants and as contemplated by the Registration Statement,
the Disclosure Package and the Prospectus, except with respect to applicable federal and state securities laws and the rules and regulations
of the Financial Industry Regulatory Authority, Inc. (&ldquo;</FONT>FINRA<FONT STYLE="font-weight: normal">&rdquo;).</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.16
<U>D&amp;O Questionnaires</U>. To the Company&rsquo;s knowledge, all information contained in the FINRA questionnaires (the &ldquo;</FONT><FONT STYLE="font-style: normal">Questionnaires<FONT STYLE="font-weight: normal">&rdquo;)
completed by each of the Company&rsquo;s directors, officers, and principal shareholders immediately prior to the Offering (the &ldquo;</FONT>Insiders<FONT STYLE="font-weight: normal">&rdquo;)
as supplemented by all information concerning the Company&rsquo;s directors, officers and principal shareholders as described in the Registration
Statement, the Disclosure Package and the Prospectus, as well as in the Lock-Up Agreements (as defined in <U>Section 2.26</U>), provided
to the Underwriter is true and correct in all material respects and the Company has not become aware of any information that would cause
the information disclosed in the Questionnaires to become inaccurate and incorrect in any material respect.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.17
<U>Litigation; Governmental Proceedings</U>. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or
governmental proceeding pending or, to the Company&rsquo;s knowledge, threatened against, or involving the Company or the Subsidiary,
or to the Company&rsquo;s knowledge, any executive officer or director that has not been disclosed in the Registration Statement, the
Disclosure Package and the Prospectus, which if resolved adversely to the Company is reasonably likely to result in a Material Adverse
Change or is required to be disclosed. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.18 <U>Good
Standing</U>. Each of the Company and the Subsidiary has been duly organized and
is validly existing as a corporation and is in good standing under the laws of its jurisdiction of incorporation as of the date hereof,
and is duly qualified to do business and is in good standing in each other jurisdiction in which its ownership or lease of property or
the conduct of business requires such qualification, except where the failure to qualify, singularly or in the aggregate, would not have
or reasonably be expected to result in a Material Adverse Change.</font>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.19
<U>Insurance</U>. Each of the Company and the Subsidiary carries or is entitled to the benefits of insurance (including, without limitation,
as to directors and officers insurance coverage) with reputable insurers, in such amounts and covering such risks which the Company reasonably
believes are adequate, and all such insurance is in full force and effect. Neither the Company nor the Subsidiary have any reason to believe
that it will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage
from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result
in a Material Adverse Change.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.20
<U>Transactions Affecting Disclosure to FINRA</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.20.1.
<U>Finder&rsquo;s Fees</U>. There are no claims, payments, arrangements, agreements or understandings relating to the payment of a finder&rsquo;s,
consulting or origination fee by the Company, the Subsidiary or any Insider with respect to the sale of the Public Securities hereunder
or any other arrangements, agreements or understandings of the Company or, to the Company&rsquo;s knowledge, any of its shareholders that
may affect the Underwriter&rsquo;s compensation, as determined by FINRA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.20.2.
<U>Payments Within Twelve (12) Months</U>. The Company has not made any direct or indirect payments (in cash, securities or otherwise)
to: (i)&nbsp;any person, as a finder&rsquo;s fee, consulting fee or otherwise, in consideration of such person raising capital for the
Company or introducing to the Company persons who raised or provided capital to the Company; (ii) any FINRA member; or (iii) any
person or entity that has any direct or indirect affiliation or association with any FINRA member, within the twelve (12) months prior
to the Effective Date, other than the payment to the Underwriter as provided hereunder in connection with the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.20.3.
<U>Use of Proceeds</U>. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or its
affiliates, except as specifically authorized herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.20.4.
<U>FINRA Affiliation</U>. There is no officer or director of the Company or beneficial owner of 10% or more of any class of the Company&rsquo;s
securities or equity-linked securities that is an affiliate or associated person of a FINRA member participating in the Offering (as determined
in accordance with the rules and regulations of FINRA). Neither the Company nor any of its affiliates (within the meaning of FINRA&rsquo;s
Conduct Rule 5121(f)(i)) directly or indirectly controls, is controlled by, or is under common control with, or is an associated person
(within the meaning of Article 1, Section 1(ee) of the By-Laws of FINRA) of, any member of FINRA participating in the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.20.5.
<U>Information</U>. All information provided by the Company in its FINRA questionnaire to Underwriter&rsquo;s Counsel specifically for
use by Underwriter&rsquo;s Counsel in connection with its Public Offering System filings (and related disclosure) with FINRA is true,
correct and complete in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.21 <U>Foreign
Corrupt Practices Act</U>. Neither the Company, the Subsidiary nor, to the Company&rsquo;s knowledge, any director, officer, agent,
employee or affiliate of the Company, the Subsidiary nor any other person acting on behalf of the Company or the Subsidiary, has,
directly or indirectly, given or agreed to give any money, gift or similar benefit (other than legal price concessions to customers
in the ordinary course of business) to any customer, supplier, employee or agent of a customer or supplier, or official or employee
of any governmental agency or instrumentality of any government (domestic or foreign) or any political party or candidate for office
(domestic or foreign) or other person who was, is, or may be in a position to help or hinder the business of the Company or the
Subsidiary (or assist it in connection with any actual or proposed transaction) that (i)&nbsp;might subject the Company or the
Subsidiary to any damage or penalty in any civil, criminal or
governmental litigation or proceeding, (ii)&nbsp;if not given in the past, might have had a Material Adverse Change or (iii)&nbsp;if not
continued in the future, might adversely affect the assets, business, operations or prospects of the Company <FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">or
the Subsidiary. Each of the Company and each Subsidiary has taken reasonable steps to ensure that its accounting controls and procedures
are sufficient to cause the Company and the Subsidiary to comply in all material respects with the Foreign Corrupt Practices Act of 1977,
as amended.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.22
<U>Compliance with OFAC</U>. Neither the Company, the Subsidiary nor, to the Company&rsquo;s knowledge, any director, officer, agent,
employee or affiliate of the Company, the Subsidiary nor any other person acting on behalf of the Company or the Subsidiary, is currently
subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (&ldquo;</FONT><FONT STYLE="font-style: normal">OFAC<FONT STYLE="font-weight: normal">&rdquo;),
and the Company will not, directly or indirectly, use the proceeds of the Offering hereunder, or lend, contribute or otherwise make available
such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person
currently subject to any U.S. sanctions administered by OFAC.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.23
<U>Money Laundering Laws</U>. To the Company&rsquo;s knowledge after due inquiry, the operations of the Company and the Subsidiary are
and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency
and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules and regulations
thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively,
the &ldquo;</FONT><FONT STYLE="font-style: normal">Money Laundering Laws<FONT STYLE="font-weight: normal">&rdquo;); and no action, suit
or proceeding by or before any Governmental Entity involving the Company or the Subsidiary with respect to the Money Laundering Laws is
pending or, to the best knowledge of the Company, threatened.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.24
<U>Forward-Looking Statements</U>. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E
of the Exchange Act) contained in either the Registration Statement, the Disclosure Package or the Prospectus has been made or reaffirmed
without a reasonable basis or has been disclosed other than in good faith.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.25
<U>Officers&rsquo; Certificate</U>. Any certificate pursuant to this Agreement signed by any duly authorized officer of the Company and
delivered to you or to Underwriter&rsquo;s Counsel shall be deemed a representation and warranty by the Company to the Underwriter as
to the matters covered thereby.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.26
<U>Lock-Up Agreements. Schedule 2</U> hereto contains a complete and accurate list of the Company&rsquo;s executive officers and directors
as well as any stockholders deemed to be affiliates through their ownership of shares of the Company&rsquo;s Common Stock (collectively,
the &ldquo;</FONT><FONT STYLE="font-style: normal">Lock-Up Parties<FONT STYLE="font-weight: normal">&rdquo;). The Company has caused each
of the Lock-Up Parties to deliver to the Underwriter an executed Lock-Up Agreement, in the form attached hereto as <U>Exhibit A</U> (the
&ldquo;</FONT>Lock-Up Agreement<FONT STYLE="font-weight: normal">&rdquo;), prior to the execution of this Agreement. </FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.27
<U>Subsidiaries</U>. The Company owns all of the capital stock and/or the equity interests in Quasuras, Inc., a Delaware corporation (the
&ldquo;</FONT><FONT STYLE="font-style: normal">Subsidiary<FONT STYLE="font-weight: normal">&rdquo;). The Company has no other interest,
nominal or beneficial, direct or indirect, in any other corporation, partnership, limited liability company, joint venture or other business
entity. All of the outstanding shares of capital stock and/or equity interests of the Subsidiary have been duly authorized and validly
issued, are fully paid and non-assessable and, except to the extent set forth in the Registration Statement or the Prospectus, are owned
by the Company directly or indirectly through one or more wholly-owned subsidiaries, free and clear of any claim, lien, encumbrance, security
interest, restriction upon voting or transfer or any other claim of any third party. Except as disclosed in the Registration Statement
or the Prospectus, no director, officer, or key employee of the Company named in the Prospectus holds any direct equity, debt or other
pecuniary interest in the Subsidiary or, to the best of the Company&rsquo;s knowledge,
any individual or entity with whom the Company or the Subsidiary does business or with which it is in privity of contract.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.28
<U>Related Party Transactions</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.28.1.
<U>Business Relationships</U>. There are no business relationships or related party transactions involving the Company or the Subsidiary
or any other person required to be described in the Registration Statement, the Disclosure Package and the Prospectus that have not been
described as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.28.2.
<U>No Relationships with Customers and Suppliers</U>. No relationship, direct or indirect, exists between or among the Company or the
Subsidiary on the one hand, and the directors, officers, 5% or greater shareholders, customers or suppliers of the Company or the Subsidiary
or any of the Company&rsquo;s affiliates on the other hand, which is required to be described in the Registration Statement, the Disclosure
Package and the Prospectus or a document incorporated by reference therein and which is not so described.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.28.3.
<U>No Unconsolidated Entities</U>. There are no transactions, arrangements or other relationships between and/or among the Company or
the Subsidiary, any of the Company&rsquo;s affiliates (as such term is defined in Rule 405 of the Securities Act) and any unconsolidated
entity, including, but not limited to, any structured finance, special purpose or limited purpose entity that could reasonably be expected
to materially affect the Company&rsquo;s liquidity or the availability of or requirements for its capital resources required to be described
in the Disclosure Package and the Prospectus or a document incorporated by reference therein which have not been described as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.28.4.
<U>No Loans or Advances to Affiliates</U>. There are no outstanding loans, advances (except normal advances for business expenses in the
ordinary course of business) or guarantees or indebtedness by the Company to or for the benefit of any of the officers or directors of
the Company or any of their respective family members, except as disclosed in the Registration Statement, the Disclosure Package and the
Prospectus. All transactions by the Company with its officers or directors or control persons of the Company have been duly approved by
the Board of Directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.29
<U>Board of Directors</U>. The Board of Directors of the Company is comprised of the persons set forth in the Registration Statement,
each Preliminary Prospectus and the Prospectus. The qualifications of the persons serving as board members and the overall composition
of the board comply with the Exchange Act, the rules and regulations of the Commission under the Exchange Act Regulations, the Sarbanes-Oxley
Act of 2002 and the rules promulgated thereunder (the &ldquo;</FONT><FONT STYLE="font-style: normal">Sarbanes-Oxley Act<FONT STYLE="font-weight: normal">&rdquo;)
applicable to the Company and the listing rules of the NasdaqCM. At least one member of the Audit Committee of the Board of Directors
of the Company qualifies as an &ldquo;audit committee financial expert,&rdquo; as such term is defined under Regulation S-K and the listing
rules of the NasdaqCM. In addition, at least a majority of persons serving on the Board of Directors qualify as &ldquo;independent,&rdquo;
as defined under the listing rules of the NasdaqCM.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.30
<U>Sarbanes-Oxley Compliance</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.30.1.
<U>Disclosure Controls</U>. The Company has developed and currently maintains disclosure controls and procedures that comply with Rule
13a-15 or 15d-15 under the Exchange Act Regulations, and such controls and procedures are effective to ensure that information required
to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and
reported, within the time periods specified in the Commission&rsquo;s rules and forms and includes, without limitation, controls and
procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under
the Exchange Act is accumulated and communicated to the Company&rsquo;s management, including its principal executive and principal financial
officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</FONT></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.30.2.
<U>Compliance</U>. The Company is, or at the Applicable Time and on the Closing Date and each Option Closing Date, if any, will be, in
material compliance with the provisions of the Sarbanes-Oxley Act applicable to it, and has implemented or will implement such programs
and taken reasonable steps to ensure the Company&rsquo;s future compliance (not later than the relevant statutory and regulatory deadlines
therefor) with all of the material provisions of the Sarbanes-Oxley Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.31
<U>Accounting Controls</U>. The Company maintains systems of &ldquo;internal control over financial reporting&rdquo; (as defined under
Rules 13a-15 and 15d-15 under the Exchange Act Regulations) that comply with the requirements of the Exchange Act and have been designed
by, or under the supervision of, its principal executive and principal financial officer, or persons performing similar functions, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles and includes those policies and procedures that: (1) pertain to the
maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the
Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles, and that receipts and expenditures of the issuer are being made only in accordance
with authorizations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection
of unauthorized acquisition, use or disposition of the Company&rsquo;s assets that could have a material effect on the financial statements.
Except as disclosed in the Registration Statement, the Disclosure Package and the Prospectus, the Company is not aware of any material
weaknesses in its internal controls. The Company&rsquo;s auditors and the Audit Committee of the Board of Directors of the Company have
been advised of: (i) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial
reporting which are known to the Company&rsquo;s management and that have adversely affected or are reasonably likely to adversely affect
the Company&rsquo;s ability to record, process, summarize and report financial information; and (ii) any fraud known to the Company&rsquo;s
management, whether or not material, that involves management or other employees who have a significant role in the Company&rsquo;s internal
controls over financial reporting.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.32
<U>No Investment Company Status</U>. The Company is not and, after giving effect to the Offering and the application of the proceeds thereof
as described in the Registration Statement, the Disclosure Package and the Prospectus, will not be, required to register as an &ldquo;investment
company,&rdquo; as defined in the Investment Company Act of 1940, as amended.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.33
<U>No Labor Disputes</U>. No labor dispute with the employees of the Company or the Subsidiary exists or, to the knowledge of the Company
or the Subsidiary, is imminent. The Company is not aware that any key employee or significant group of employees of the Company or the
Subsidiary plans to terminate employment with the Company or the Subsidiary.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.34
<U>Intellectual Property Rights</U>. The Company owns or possesses or has valid rights to use all patents, patent applications, trademarks,
service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, inventions, trade secrets software,
databases, know-how, internet domain names, other unpatented and/or unpatentable proprietary confidential information systems, processes
or procedures and similar rights (&ldquo;</FONT><FONT STYLE="font-style: normal">Intellectual Property Rights<FONT STYLE="font-weight: normal">&rdquo;)
necessary for the conduct of the business of the Company and the Subsidiary as currently carried on and as described in the Registration
Statement, the Disclosure Package and the Prospectus. The Intellectual Property Rights licenses described in the Registration Statement,
Disclosure Package and the Prospectus are valid, binding upon and enforceable against the parties thereto in accordance with their respective
terms. To the knowledge of the Company, no action or use by the Company or the Subsidiary necessary for the conduct of its business as
currently carried on and as described in the Registration
Statement, the Disclosure Package and the Prospectus will involve or give rise to any infringement of, or license or similar fees for,
any Intellectual Property Rights of others. <FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">None
of the Company nor the Subsidiary has received any notice alleging any such infringement, fee or conflict with asserted Intellectual Property
Rights of others. Except as would not reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change
(A) to the knowledge of the Company, there is no infringement, misappropriation or violation by third parties of any of the Intellectual
Property Rights owned by the Company or the Subsidiary; (B) there is no pending or, to the knowledge of the Company, threatened action,
suit, proceeding or claim by others challenging the rights of the Company or the Subsidiary in or to any such Intellectual Property Rights,
and the Company is unaware of any facts which would form a reasonable basis for any such claim, that would, individually or in the aggregate,
together with any other claims in this <U>Section 2.34</U>, reasonably be expected to result in a Material Adverse Change; (C) the Intellectual
Property Rights owned by the Company and, to the knowledge of the Company, the Intellectual Property Rights licensed to the Company or
the Subsidiary have not been adjudged by a court of competent jurisdiction invalid or unenforceable, in whole or in part, and there is
no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope
of any such Intellectual Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim
that would, individually or in the aggregate, together with any other claims in this <U>Section 2.34</U>, reasonably be expected to result
in a Material Adverse Change; (D) there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim
by others that the Company or the Subsidiary infringes, misappropriates or otherwise violates any Intellectual Property Rights or other
proprietary rights of others, none of the Company nor the Subsidiary has received any written notice of such claim and the Company is
unaware of any other facts which would form a reasonable basis for any such claim that would, individually or in the aggregate, together
with any other claims in this <U>Section 2.34</U>, reasonably be expected to result in a Material Adverse Change; and (E) to the Company&rsquo;s
knowledge, no employee of the Company or the Subsidiary is in or has ever been in violation in any material respect of any term of any
employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement,
nondisclosure agreement or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee&rsquo;s
employment with the Company or the Subsidiary, or actions undertaken by the employee while employed with the Company or the Subsidiary
and could reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change. To the Company&rsquo;s knowledge,
all material technical information developed by and belonging to the Company or the Subsidiary which has not been patented has been kept
confidential. None of the Company nor the Subsidiary is a party to or bound by any options, licenses or agreements with respect to the
Intellectual Property Rights of any other person or entity that are required to be set forth in the Registration Statement, the Disclosure
Package and the Prospectus and are not described therein. The Registration Statement, the Disclosure Package and the Prospectus contain
in all material respects the same description of the matters set forth in the preceding sentence. None of the technology employed by the
Company or the Subsidiary has been obtained or is being used by the Company in violation of any contractual obligation binding on the
Company or the Subsidiary or, to the Company&rsquo;s knowledge, any of their officers, directors or employees, or otherwise in violation
of the rights of any persons. </FONT></FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.35
<U>Taxes</U>. Each of the Company and the Subsidiary has filed all returns (as hereinafter defined) required to be filed with taxing
authorities prior to the date hereof or has duly obtained extensions of time for the filing thereof. Each of the Company and the Subsidiary
has paid all taxes (as hereinafter defined) shown as due on such returns that were filed and has paid all taxes imposed on or assessed
against the Company or the Subsidiary. The provisions for taxes payable, if any, shown on the financial statements filed with or as part
of the Registration Statement are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and including
the dates of such consolidated financial statements. Except as disclosed in writing to the Underwriter, (i) no issues have been raised
(and are currently pending) by any taxing authority in connection with any of the returns or taxes asserted as due from the Company or
the Subsidiary, and (ii) no waivers of statutes of limitation with respect to the returns or collection of taxes have been given by or
requested from the Company <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">or the Subsidiary.
There are no tax liens against the assets, properties or business of the Company or the Subsidiary. The term &ldquo;</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal"><B>taxes</B><FONT STYLE="font-style: normal; font-weight: normal">&rdquo;
means all federal, state, local, foreign and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise,
profits, license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property,
windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatever, together with any interest and any
penalties, additions to tax or additional amounts with respect thereto. The term &ldquo;</FONT><B>returns</B><FONT STYLE="font-style: normal; font-weight: normal">&rdquo;
means all returns, declarations, reports, statements and other documents required to be filed in respect to taxes.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.36
<U>Compliance with Environmental Laws</U>. Except as described in the Registration Statement, the Disclosure Package and the Prospectus
and except as would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Change, (i) none of the Company
nor the Subsidiary n is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or
rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent,
decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air,
surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating
to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum
or petroleum products (collectively, &ldquo;</FONT><FONT STYLE="font-style: normal">Hazardous Materials<FONT STYLE="font-weight: normal">&rdquo;)
or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively,
&ldquo;</FONT>Environmental Laws<FONT STYLE="font-weight: normal">&rdquo;), (ii) each of the Company and the Subsidiary has all material
permits, authorizations and approvals required under any applicable Environmental Laws and is in compliance with their requirements, (iii)
there are no pending or, to the Company&rsquo;s knowledge, threatened administrative, regulatory or judicial actions, suits, demands,
demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against
the Company or the Subsidiary and (iv) to the Company&rsquo;s knowledge, there are no events, conditions, incidents or circumstances that
might reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private
party or governmental body or agency, against or affecting the Company or the Subsidiary relating to Hazardous Materials or any Environmental
Laws.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.37
<U>ERISA Compliance</U>. The Company, each Subsidiary and any &ldquo;employee benefit plan&rdquo; (as defined under the Employee Retirement
Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &ldquo;</FONT><FONT STYLE="font-style: normal">ERISA<FONT STYLE="font-weight: normal">&rdquo;))
established or maintained by the Company or its &ldquo;ERISA Affiliates&rdquo; (as defined below) are in compliance in all material respects
with ERISA. &ldquo;</FONT>ERISA Affiliate<FONT STYLE="font-weight: normal">&rdquo; means, with respect to the Company, any member of
any group of organizations described in Sections 414(b),(c),(m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations
and published interpretations thereunder (the &ldquo;</FONT>Code<FONT STYLE="font-weight: normal">&rdquo;) of which the Company is a
member. No &ldquo;reportable event&rdquo; (as defined under ERISA) has occurred or is reasonably expected to occur with respect to any
&ldquo;employee benefit plan&rdquo; established or maintained by the Company or any of its ERISA Affiliates. No &ldquo;employee benefit
plan&rdquo; established or maintained by the Company or any of its ERISA Affiliates, if such &ldquo;employee benefit plan&rdquo; were
terminated, would have any &ldquo;amount of unfunded benefit liabilities&rdquo; (as defined under ERISA). Neither the Company nor any
of its ERISA Affiliates has incurred or reasonably expects to incur any material liability under (i) Title IV of ERISA with respect to
termination of, or withdrawal from, any &ldquo;employee benefit plan&rdquo; or (ii) Sections 412, 4971, 4975 or 4980B of the Code. Each
&ldquo;employee benefit plan&rdquo; established or maintained by the Company or any of its ERISA Affiliates that is intended to be qualified
under Section 401(a) of the Code is so qualified and, to the knowledge of the Company, nothing has occurred, whether by action or failure
to act, which would cause the loss of such qualification. The execution of this Agreement, or consummation of the Offering does not constitute
a triggering event under any employee benefit plan or any other employment contract, whether or not legally enforceable, which (either
alone or upon the occurrence of any additional or subsequent event) will or may result in any payment (of severance pay or otherwise),
acceleration, increase in vesting, or increase in benefits to any current or former participant, employee or director of the Company
other than an event that is not material to the financial condition or business of the Company and the Subsidiary taken as a whole.</FONT></FONT></P>




<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.38
<U>Compliance with Laws</U>. Each of the Company and the Subsidiary: (A) is and at all times has been in material compliance with all
statutes, rules, or regulations applicable to the conduct of the business of the Company or the Subsidiary (collectively, the &ldquo;</FONT><FONT STYLE="font-style: normal">Applicable
Laws<FONT STYLE="font-weight: normal">&rdquo;), except as could not, individually or in the aggregate, reasonably be expected to have
a Material Adverse Change; (B) has not received any warning letter, untitled letter or other correspondence or notice from any other Governmental
Entity alleging or asserting noncompliance with any Applicable Laws or any Authorizations; (C) possesses all material Authorizations and
such Authorizations are valid and in full force and effect and the Company is not in material violation of any term of any such Authorizations;
(D) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from
any Governmental Entity or third party alleging that any of the Company&rsquo;s activities is in violation of any Applicable Laws or Authorizations
and has no knowledge that any such Governmental Entity or third party is considering any such claim, litigation, arbitration, action,
suit, investigation or proceeding; (E) has not received notice that any Governmental Entity has taken, is taking or intends to take action
to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such governmental authority is considering such action;
and (F) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions
and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments were complete and correct on the date filed (or were corrected
or supplemented by a subsequent submission).</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.39
<U>Company IT Systems</U>. Except as described in the Registration Statement, the Disclosure Package and the Prospectus, the Company owns
or has a valid right to access and use all computer systems, networks, hardware, software, databases, websites and equipment used to process,
store, maintain and operate data, information and functions necessary for the conduct of its business (the &ldquo;</FONT><FONT STYLE="font-style: normal">Company
IT Systems<FONT STYLE="font-weight: normal">&rdquo;), except where the failure to own or have the right to access the Company IT Systems
would not reasonably be expected to have a Material Adverse Change. The Company IT Systems are adequate for, and operate and perform in
all material respects as required in connection with, the operation of the business of the Company as currently conducted except as would
not be reasonably expected, individually or in the aggregate, to have a Material Adverse Change.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.40
<U>Health Care Authorizations</U>. The Company has submitted and possesses, or qualifies for applicable exemptions to, such valid and
current registrations, listings, approvals, clearances, licenses, certificates, authorizations or permits and supplements or amendments
thereto (collectively, &ldquo;</FONT><FONT STYLE="font-style: normal">Health Care Authorizations<FONT STYLE="font-weight: normal">&rdquo;)
issued or required by the appropriate local, state, federal, national, supranational or other foreign regulatory agencies or bodies (collectively,
&ldquo;</FONT>Health Regulatory Agencies<FONT STYLE="font-weight: normal">&rdquo;) necessary to conduct its business as described in the
Registration Statement, the Disclosure Package and the Prospectus, including, without limitation, all such Health Care Authorizations
required by the U.S. Food and Drug Administration (the &ldquo;</FONT>FDA<FONT STYLE="font-weight: normal">&rdquo;), the Department of
Health and Human Services, the European Commission, the EMA or any other Health Regulatory Agencies engaged in the regulation of Biologics
(as defined in the Public Health Service Act of 1944, as amended (42 U.S.C. 6A et seq.)), except as would not be reasonably expected to
result in a Material Adverse Change. The Company has not received any notice of proceedings, or have any knowledge of any threatened proceedings,
relating to the revocation or modification of, or non-compliance with, any such Health Care Authorization, except where such revocation,
modification or non-compliance would not result in a Material Adverse Change.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.41
<U>Compliance with Health Care Laws</U>. The Company is, and has been, in compliance in all material respects with all applicable Health
Care Laws, and has not engaged in activities which are, as applicable, cause for false claims liability, civil penalties, or mandatory
or permissive exclusion from Medicare, Medicaid or any other state, federal or national health care program. For purposes of this Agreement,
&ldquo;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal"><B>Health Care Laws</B><FONT STYLE="font-style: normal; font-weight: normal">&rdquo;
means all health care laws and regulations applicable to the Company, including, but not limited to: the Federal Food, Drug, and Cosmetic
Act (21 U.S.C. Section 301 et seq.), the Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the Civil Monetary Penalties Law (42
U.S.C. &sect; 1320a-7a), the Physician Payments Sunshine Act (42 U.S.C. &sect; 1320a-7h), the Civil False Claims Act (31 U.S.C. Section
3729 et seq.), the criminal False Claims Law (42 U.S.C. &sect; 1320a-7b(a)), all criminal laws relating to health care fraud and abuse,
including but not limited to 18 U.S.C. Sections 286 and 287, and the health care fraud criminal provisions under the U.S. Health Insurance
Portability and Accountability Act of 1996 (&ldquo;HIPAA&rdquo;) (42 U.S.C. Section 1320d et seq.), the exclusion laws (42 U.S.C. &sect;
1320a-7), Basic Health and Human Services Policy for Protection of Human Research Subjects &ldquo;Common Rule&rdquo; as codified and
enforced by the Department of Health and Human Services in 45 C.F.R. part 46 and enforced by FDA under 21 C.F.R. part 50, Laboratory
Animal Welfare Act of 1966, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section
17921 et seq.), the Controlled Substances Act (2 U.S.C. &sect; 801, et seq.), Good Manufacturing Practices (21 C.F.R. &sect;&sect;210
&amp; 211), Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX of the Social Security Act), any and all other applicable
comparable local, state, federal, national, supranational and foreign health care laws and the regulations promulgated pursuant to such
laws, each as amended from time to time. The Company has not received written notice of any claim, action, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third
party alleging that any product operation or activity is in material violation of any Health Care Laws, and, to the knowledge of the
Company, no such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action is threatened. The
Company has not received any written notice of adverse filing, warning letter, untitled letter or other correspondence or notice from
the FDA, the European Commission, the EMA, or any other Health Regulatory Agencies, or any other court or arbitrator, alleging or asserting
material noncompliance with the Health Care Laws. The Company is not a party to and has no ongoing reporting obligations pursuant to
any corporate integrity agreements, deferred prosecution agreements, monitoring agreements, consent decrees, settlement orders, plans
of correction or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company, nor,
to the knowledge of the Company, any of its employees, officers or directors has been excluded, suspended or debarred from participation
in any U.S. federal health care program or human research study or trial or, to the knowledge of the Company, is subject to a governmental
inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension or exclusion.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.42
<U>Research Studies and Trials</U>. (A) The research studies and trials conducted by or, to the Company&rsquo;s knowledge, on behalf of,
or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Disclosure
Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Disclosure Package or the Prospectus,
as applicable, were and, if still pending, are being, conducted in all material respects in accordance with applicable experimental protocols,
procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates
comparable to those being developed by the Company and all applicable statutes, rules and other regulations of the FDA, National Institute
of Health Department of Health and Human Services, the European Commission, the EMA, and any other Health Regulatory Agencies to which
it is subject; (B) the descriptions of the results of such studies and trials contained in the Registration Statement, the Disclosure
Package and the Prospectus do not contain any misstatement of a material fact or omit to state a material fact necessary to make such
statements not misleading; (C) the Company has no knowledge of any research studies or trials not described in the Registration Statement,
the Disclosure Package or the Prospectus the results of which reasonably call into question in any material respect the results of the
research studies and trials described in the Registration Statement, the Disclosure Package or the Prospectus or that suggest a reasonable
possibility of any adverse side effects not described in the Registration Statement, the Disclosure Package and the Prospectus; (D) the
Company has not received any notices or correspondence from the FDA, the European Commission, the EMA, or any Health Regulatory Agency
or any institutional review board or comparable authority requiring or
threatening the premature termination, suspension, material modification or clinical hold of any research studies or trials conducted
by or on behalf of, or sponsored by, the Company or in which the Company has participated that are described in the Registration Statement,
the Disclosure Package or the Prospectus, and, to the Company&rsquo;s knowledge, there are no reasonable grounds for the same; (E) there
has not been any violation of applicable law or regulation by the Company in any of its product development efforts, submissions or reports
to the FDA, the European Commission, the EMA, or any other Health Regulatory Agency that could reasonably be expected to require investigation,
corrective action or result in enforcement action, except where such violation would not, singly or in the aggregate, result in a Material
Adverse Change; and (F) the research studies and clinical trials of Company are being conducted in an ethical and humane manner under
state, national or supra-national applicable laws that are either equal or more stringent than applicable laws and regulations enforced
by the Department of Health and Human Services and FDA governing human, animal or non-human primate research participants and test subjects
and such studies and the clinical trials are conducted under the auspices of a neutral and independent Institutional Animal Care and Use
Committee or Institutional Review Board and applicable state, national, or supra national agencies responsible for oversight<FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.43
<U>Health Care Products Manufacturing</U>. The manufacture of the Company&rsquo;s products by the Company or, to the knowledge of the
Company, on behalf of the Company, is being conducted in compliance with all applicable Health Care Laws pertaining to the manufacture
and post market surveillance of Drugs, Devices, and Biologics, including, without limitation, the FDA&rsquo;s current good manufacturing
practice regulations pertaining to drugs (21 CFR Parts 210 and 211 et seq.), and, to the extent applicable, the respective counterparts
governing manufacturing operations promulgated by other Health Regulatory Agencies. Except as disclosed in the Registration Statement,
the Disclosure Package and the Prospectus, the Company has not had any manufacturing site (whether owned by the Company or, to the knowledge
of the Company, that of a third party manufacturer of the Company&rsquo;s products) subject to an FDA or other Health Regulatory Agency
consent decree, seizure, import alert, or export prohibition, nor received any FDA or other Health Regulatory Agency &ldquo;warning letters,&rdquo;
or &ldquo;untitled letters&rdquo; alleging or asserting material noncompliance with any applicable Health Care Laws, requests to make
material changes to the Company&rsquo;s products, processes or operations from the FDA or other Health Regulatory Agency, other than those
that have been satisfactorily addressed and/or closed with the FDA or other Health Regulatory Agency. To the knowledge of the Company,
none of the FDA or any other Health Regulatory Agency is considering such action.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.44
<U>Smaller Reporting Company</U>. As of the effective date of the Registration Statement and the date of this Agreement, the Company
was a &ldquo;smaller reporting company,&rdquo; as defined in Rule&nbsp;12b-2 of the Exchange Act Regulations.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.45
<U>Industry Data</U>. The statistical and market-related data included in each of the Registration Statement, the Disclosure Package
and the Prospectus are based on or derived from sources that the Company reasonably and in good faith believes are reliable and accurate
or represent the Company&rsquo;s good faith estimates that are made on the basis of data derived from such sources.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.46
<U>Margin Securities</U>. None of the Company nor the Subsidiary owns any &ldquo;margin securities&rdquo; as that term is defined in Regulation
U of the Board of Governors of the Federal Reserve System (the &ldquo;</FONT><FONT STYLE="font-style: normal">Federal Reserve Board<FONT STYLE="font-weight: normal">&rdquo;),
and none of the proceeds of the Offering will be used, directly or indirectly, for the purpose of purchasing or carrying any margin security,
for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase or carry any margin security or for
any other purpose which might cause any of the shares of Common Stock to be considered a &ldquo;purpose credit&rdquo; within the meanings
of Regulation T, U or X of the Federal Reserve Board.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.47
<U>Integration</U>. None of the Company nor the Subsidiary or affiliates, nor any person acting on its or their behalf has, directly or
indirectly, made any offers or sales of any security or solicited any offers to buy any security, under
circumstances that would cause the Offering to be integrated with prior offerings by the Company for purposes of the Securities Act that
would require the registration of <FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">the
offering of any such securities under the Securities Act.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.48
<U>Title to Real and Personal Property</U>. Each of the Company and the Subsidiary has good and marketable title in fee simple to, or
has valid rights to lease or otherwise use, all items of real or personal property that are material to the business of the Company and
the Subsidiary taken as a whole, free and clear of all liens, encumbrances, security interests, claims and defects that do not, singularly
or in the aggregate, result in a Material Adverse Change and do not interfere with the use made of such property by the Company or the
Subsidiary; and all of the leases and subleases material to the business of the Company and the Subsidiary taken as a whole, and under
which the Company or the Subsidiary holds properties described in the Registration Statement, the Disclosure Package and the Prospectus,
are, to the Company&rsquo;s knowledge in full force and effect, and neither the Company nor the Subsidiary has received any notice of
any material claim of any sort that has been asserted by anyone adverse to the rights of the Company or the Subsidiary under any of the
leases or subleases mentioned above, or affecting or questioning the rights of the Company or the Subsidiary to the continued possession
of the leased or subleased premises under any such lease or sublease, which would result in a Material Adverse Change.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.49
<U>Confidentiality and Non-Competition Agreements</U>. To the Company&rsquo;s knowledge, no director, officer, key employee or consultant
of the Company or the Subsidiary is subject to any confidentiality, non-disclosure, non-competition agreement or non-solicitation agreement
with any employer or prior employer that could materially affect his ability to be and act in his respective capacity of the Company or
the Subsidiary or be expected to result in a Material Adverse Change.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.50
<U>Corporate Records</U>. The minute books of the Company and each Subsidiary have been made available to the Underwriter and the Underwriter&rsquo;s
Counsel, and such books (i) contain a summary of all meetings and actions of the board of directors (including each board committee) and
shareholders of the Company, and (ii) reflect all material transactions referred to in such minutes.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.51
<U>Diligence Materials</U>. The Company has provided to the Company and the Underwriter&rsquo;s Counsel all materials responsive in all
material respects to the diligence requests, if any, submitted to the Company or its counsel by the Underwriter.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.52
<U>Nasdaq Marketplace Rules</U></FONT><FONT STYLE="font-weight: normal">. <FONT STYLE="font-style: normal"> The Company is, and after
giving effect to the Offering will be, in compliance in all material respects with all applicable corporate governance requirements set
forth in the Nasdaq Marketplace Rules.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-weight: normal">3.</FONT> <FONT STYLE="font-weight: normal"><U>Covenants of the Company</U>. The Company covenants and agrees as follows:</FONT></P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.1
<U>Amendments to Registration Statement</U>. The Company shall deliver to the Underwriter, prior to filing, any amendment or supplement
to the Registration Statement, any Preliminary Prospectus, any issuer Free Writing Prospectus, the Disclosure Package or the Prospectus
proposed to be filed after the Effective Date and not file any such amendment, supplement or document to which the Underwriter shall reasonably
object in writing. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.2
<U>Federal Securities Laws</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.1.
<U>Compliance</U>. The Company, subject to <U>Section 3.2.2</U>, shall comply with the requirements of Rule 424(b) and Rule 430A of the
Securities Act Regulations, and will notify the Underwriter promptly, and confirm the notice in writing, (i)&nbsp;when any post-effective
amendment to the Registration Statement or any amendment or supplement to any Preliminary Prospectus, the Disclosure Package or the Prospectus
shall have been filed and when any post-effective amendment to the Registration Statement shall become effective<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal">;
(ii)&nbsp;of the receipt of any comments from the Commission; (iii)&nbsp;of any request by the Commission for any amendment to the Registration
Statement or any amendment or supplement to any Preliminary Prospectus, the Disclosure Package or the Prospectus or for additional information;
(iv)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective
amendment or of any order preventing or suspending the use of any Preliminary Prospectus or the Prospectus, or of the suspension of the
qualification of the Public Securities for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings
for any of such purposes or of any examination pursuant to Section&nbsp;8(d) or 8(e) of the Securities Act concerning the Registration
Statement; and (v)&nbsp;if the Company becomes the subject of a proceeding under Section 8A of the Securities Act in connection with
the Offering of the Public Securities. The Company shall effect all filings required under Rule 424(b) of the Securities Act Regulations,
in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and shall take such steps as it
deems necessary to ascertain promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing
by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company shall use its commercially reasonable
efforts to prevent the issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof
at the earliest possible moment.</FONT></FONT></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.2.
<U>Continued Compliance</U>. The Company shall comply with the Securities Act, the Securities Act Regulations, the Exchange Act and the
Exchange Act Regulations so as to permit the completion of the distribution of the Public Securities as contemplated in this Agreement
and in the Registration Statement, the Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Public
Securities is (or, but for the exception afforded by Rule 172 of the Securities Act Regulations (&ldquo;</FONT>Rule 172<FONT STYLE="font-weight: normal">&rdquo;),
would be) required by the Securities Act to be delivered in connection with sales of the Public Securities, any event shall occur or condition
shall exist as a result of which it is necessary, in the opinion of Underwriter&rsquo;s Counsel or Company Counsel (as defined below),
to (i)&nbsp;amend the Registration Statement in order that the Registration Statement will not include an untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; (ii)&nbsp;amend
or supplement the Disclosure Package or the Prospectus in order that the Disclosure Package or the Prospectus, as the case may be, will
not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein
not misleading in the light of the circumstances existing at the time it is delivered to a purchaser; or (iii)&nbsp;amend the Registration
Statement or amend or supplement the Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements
of the Securities Act or the Securities Act Regulations, the Company will promptly (A)&nbsp;give the Underwriter notice of such event;
(B)&nbsp;prepare any amendment or supplement as may be necessary to correct such statement or omission or to make the Registration Statement,
the Disclosure Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or
use, furnish the Underwriter with copies of any such amendment or supplement; and (C)&nbsp;file with the Commission any such amendment
or supplement; <I>provided, however</I>, that the Company shall not file or use any such amendment or supplement to which the Underwriter
or Underwriter&rsquo;s Counsel shall reasonably object. The Company will furnish to the Underwriter such number of copies of such amendment
or supplement as the Underwriter may reasonably request. The Company will give the Underwriter notice of its intention to make any such
filing from the Applicable Time until the earlier of the last Option Closing Date, if any, and the expiration date of the Over-allotment
Option and will furnish the Underwriter with copies of the related document(s) a reasonable amount of time prior to such proposed filing,
as the case may be, and will not file or use any such document to which the Underwriter or Underwriter&rsquo;s Counsel shall reasonably
object. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.3.
<U>Exchange Act Registration</U>. For a period of two (2) years after the date of this Agreement, the Company shall use its commercially
reasonable efforts to maintain the registration of the Common Stock under the Exchange Act. The Company shall not deregister the Common
Stock under the Exchange Act without the prior written consent of the Underwriter<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal">,
which consent shall not unreasonably be withheld.</FONT></FONT></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.3.1.&nbsp;
<U>Free Writing Prospectuses.</U>&nbsp;The Company agrees that, unless it obtains the prior written consent of the Underwriter, it shall
not make any offer relating to the Public Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute
a &ldquo;free writing prospectus,&rdquo; or a portion thereof, required to be filed by the Company with the Commission or retained by
the Company under Rule 433; <I><U>provided</U></I> that the Underwriter shall be deemed to have consented to each Issuer General Use Free
Writing Prospectus listed in <U>Schedule 1-B</U> and any &ldquo;road show that is a written communication&rdquo; within the meaning of
Rule 433(d)(8)(i) that has been reviewed by the Underwriter. The Company represents that it has treated or agrees that it will treat each
such free writing prospectus consented to, or deemed consented to, by the Underwriter as an &ldquo;issuer free writing prospectus,&rdquo;
as defined in Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433 with respect thereto, including
timely filing with the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing
Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would
conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material fact
or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
existing at that subsequent time, not misleading, the Company will promptly notify the Underwriter and will promptly amend or supplement,
at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.3
<U>Delivery to the Underwriter of Registration Statements</U>. The Company has delivered or made available or shall deliver or make available
to the Underwriter and Underwriter&rsquo;s Counsel, without charge, signed copies of the Registration Statement as originally filed and
each amendment thereto (including exhibits filed therewith) and signed copies of all consents and certificates of experts, and will also
deliver to the Underwriter, without charge, a conformed copy of the Registration Statement as originally filed and each amendment thereto
(without exhibits) for the Underwriter. The copies of the Registration Statement and each amendment thereto furnished to the Underwriter
will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted
by Regulation S-T.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.4
<U>Delivery to the Underwriter of Prospectuses</U>. The Company has delivered or made available or will deliver or make available to the
Underwriter, without charge, as many copies of each Preliminary Prospectus and the Disclosure Package as the Underwriter reasonably requests,
and the Company hereby consents to the use of such copies for purposes permitted by the Securities Act. The Company will furnish to the
Underwriter, without charge, during the period when a prospectus relating to the Public Securities is (or, but for the exception afforded
by Rule 172 of the Securities Act Regulations, would be) required to be delivered under the Securities Act, such number of copies of the
Prospectus (as amended or supplemented) as the Underwriter may reasonably request. The Prospectus and any amendments or supplements thereto
furnished to the Underwriter will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to
EDGAR, except to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.5
<U>Effectiveness and Events Requiring Notice to the Underwriter</U>. The Company shall use commercially reasonable efforts to cause the
Registration Statement (or another registration statement registering the offer and sale of the Public Securities and the Underwriter&rsquo;s
Securities under the Securities Act) to remain effective with a current prospectus until the latest of (a) nine (9) months after the Applicable
Time, (b) the date that the Warrants have been exercised in full or expired by their terms and (c) the date that the Underwriter&rsquo;s
Warrant has been exercised in full or expired by its terms. The Company shall notify the Underwriter immediately and confirm the notice
in writing: (i)&nbsp;of the effectiveness of the Registration Statement and any amendment thereto; (ii)&nbsp;of the issuance by the Commission
of any stop order or of the initiation, or the threatening, of
any proceeding for that purpose; (iii)&nbsp;of the issuance by any state securities commission of any proceedings for the suspension of
the qualification of <FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">the
Public Securities for offering or sale in any jurisdiction or of the initiation, or the threatening, of any proceeding for that purpose;
(iv)&nbsp;of the mailing and delivery to the Commission for filing of any amendment or supplement to the Registration Statement or Prospectus;
(v)&nbsp;of the receipt of any comments or request for any additional information from the Commission; and (vi)&nbsp;of the happening
of any event during the period described in this <U>Section 3.5</U> that, in the judgment of the Company, makes any statement of a material
fact made in the Registration Statement, the Disclosure Package or the Prospectus untrue or that requires the making of any changes in
(a) the Registration Statement in order to make the statements therein not misleading, or (b) in the Disclosure Package or the Prospectus
in order to make the statements therein, in light of the circumstances under which they were made, not misleading. If the Commission or
any state securities commission shall enter a stop order or suspend such qualification at any time, the Company shall make every reasonable
effort to obtain promptly the lifting of such order.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.6
<U>Review of Financial Statements.</U> For a period of five (5) years after the date of this Agreement, the Company, at its expense, shall
cause its regularly engaged independent registered public accounting firm to review (but not audit) the Company&rsquo;s financial statements
for each of the three fiscal quarters immediately preceding the announcement of any quarterly financial information.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.7
<U>Listing</U>. The Company shall use its commercially reasonable efforts to maintain the listing of the Common Stock (including the Public
Securities) on the NasdaqCM for at least two (2) years from the date of this Agreement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.8
<U>Reports to the Underwriter</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.8.1.
<U>Periodic Reports</U>. For a period of two (2) years after the date of this Agreement, the Company shall furnish or make available to
the Underwriter copies of such financial statements and other periodic and special reports as the Company from time to time furnishes
generally to holders of any class of its securities and also promptly furnish to the Underwriter: (i) a copy of each periodic report the
Company shall be required to file with the Commission under the Exchange Act and the Exchange Act Regulations; (ii) a copy of every press
release and every news item and article with respect to the Company and its affairs which was released by the Company; (iii) a copy of
each Form 8-K prepared and filed by the Company; (iv) five copies of each registration statement filed by the Company under the Securities
Act; (v) a copy of each report or other communication furnished to shareholders; and (vi) such additional documents and information with
respect to the Company and the affairs of any future subsidiaries of the Company as the Underwriter may from time to time reasonably request;
provided the Underwriter shall sign, if requested by the Company, a Regulation FD compliant confidentiality agreement which is reasonably
acceptable to the Underwriter and Underwriter&rsquo;s Counsel in connection with the Underwriter&rsquo;s receipt of such information.
Documents filed with the Commission pursuant to its EDGAR system shall be deemed to have been delivered to the Underwriter pursuant to
this <U>Section 3.8.1</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.8.2.
<U>Transfer Agent; Transfer Sheets</U>. For a period of two (2) years after the date of this Agreement, the Company shall retain a transfer
agent and registrar acceptable to the Underwriter (the&nbsp;&ldquo;</FONT>Transfer Agent<FONT STYLE="font-weight: normal">&rdquo;). Colonial
Stock Transfer, Inc. is acceptable to the Underwriter to act as Transfer Agent for the Common Stock. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.8.3.
<U>Trading Reports</U>. For a period of two (2) years after the date of this Agreement, the Company shall provide to the Underwriter,
at the Company&rsquo;s expense, such reports published by NasdaqCM relating to price trading of the Public Securities, as the Underwriter
shall reasonably request; provided that such provision shall not prevent a sale, merger or similar transaction involving the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.8.4.
<U>Payment of Expenses</U>. The Company hereby agrees to pay on the Closing Date and each Option Closing Date, if any, to the extent not
paid at the Closing Date, all expenses incident to the performance of the obligations of the Company under this Agreement, including,
but not limited to: (a) all filing fees and communication expenses relating to the registration of the Public Securities and the Underwriter&rsquo;s
Securities to be sold in the Offering (including the Option Securities) with the Commission, (b) all filing fees and other expenses (including
the reasonable fees and disbursements of Underwriter&rsquo;s Counsel) incurred in connection with qualification of the Public Securities
and the Underwriter&rsquo;s Securities for sale under the laws of such jurisdictions as the Underwriter designates, (c) costs and expenses
related to the review of the Offering by FINRA, including all filing fees and the reasonable fees and disbursements of counsel to the
Underwriter relating to such review, (d) costs and reasonable expenses relating to investor presentations or any &ldquo;road show&rdquo;
in connection with the Offering, including, without limitation, the costs of recording and hosting on the Internet of the Company&rsquo;s
road show presentation and any reasonable travel expenses of the Company&rsquo;s officers and employees and any other expenses of the
Company, (e) fees and expenses incident to listing or continued listing of the Public Securities and the Underwriter&rsquo;s Securities
on the NasdaqCM and on such other stock exchanges as the Company and the Underwriter together determine, (f) the fees, disbursements and
expenses of the Company&rsquo;s counsel, accountants and other advisors in connection with the Offering, (g) expenses incurred in preparing,
printing and distributing each Preliminary Prospectus and the Prospectus (including any amendments and supplements thereto) to the Underwriter
and for expenses incurred for preparing, printing and distributing any issuer free writing prospectuses to investors or prospective investors,
(h) reasonable fees, disbursements and expenses of the Underwriter&rsquo;s counsel, (i) the costs and expenses of a public relations firm
selected by the Company, if any, (i) the costs of preparing, printing and delivering certificates representing the Public Securities and
the Underwriter&rsquo;s Securities, (j) fees and expenses of the transfer agent for the delivery of the Public Securities and the Underwriter&rsquo;s
Securities, (k) stock transfer and/or stamp taxes, if any, payable upon the transfer of securities from the Company to the Underwriter,
(l) to the extent approved by the Company in writing, the costs associated with post-closing advertising of the Offering in the national
editions of the Wall Street Journal and New York Times, (m) fees, expenses and disbursements relating to background checks of the Company&rsquo;s
officers and directors in connection with the Offering; <U>provided</U>, <U>however</U>, that the maximum amount of fees, costs and expenses
incurred by the Underwriter with respect to subparagraphs <U>(a)</U> through <U>(m)</U> above, including, without limitation, the fees,
disbursements and expenses of Underwriter&rsquo;s Counsel, that the Company shall be required to pay under this <U>Section 3.8.4</U> shall
not exceed $125,000. The Underwriter may deduct from the net proceeds of the Offering payable to the Company on the Closing Date or any
Option Closing Date, the expenses set forth herein to be paid by the Company to the Underwriter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.9
<U>Application of Net Proceeds</U>. The Company shall apply the net proceeds from the Offering received by it in a manner consistent with
the application thereof described under the caption &ldquo;Use of Proceeds&rdquo; in the Registration Statement, the Disclosure Package
and the Prospectus.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.10
<U>Delivery of Earnings Statements to Security Holders</U>. The Company shall make generally available to its security holders as soon
as practicable, but not later than the first day of the fifteenth (15<SUP>th</SUP>) full calendar month following the date of this Agreement,
an earnings statement (which need not be certified by an independent registered public accounting firm unless required by the Securities
Act or the Securities Act Regulations, but which shall satisfy the provisions of Rule 158(a) under Section 11(a) of the Securities Act)
covering a period of at least twelve (12) consecutive months ending after the date of this Agreement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.11
<U>Stabilization</U>. Neither the Company nor, to its knowledge, any of its employees, directors or shareholders (without the consent
of the Underwriter), has taken or shall take, directly or indirectly, any action designed to or that has constituted or that might reasonably
be expected to cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of
any security of the Company to facilitate the sale or resale of the Public Securities or the Underwriter&rsquo;s Securities.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.12
<U>Internal Controls</U>. The Company shall use commercially reasonable efforts to maintain a system of internal accounting controls sufficient
to provide reasonable assurances regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles and includes those policies and procedures that: (1) pertain to the
maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the
Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance
with authorizations of management and directors of the issuer; and (3) provide reasonable assurance regarding prevention or timely detection
of unauthorized acquisition, use or disposition of the Company&rsquo;s assets that could have a material effect on the financial statements.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.13
<U>Accountants</U>. The Company shall retain an independent registered public accounting firm, as required by the Securities Act and the
Securities Act Regulations and the Public Company Accounting Oversight Board, reasonably acceptable to the Underwriter, and the Company
shall continue to retain an independent registered public accounting firm for a period of at least three (3) years after the date of this
Agreement. The Underwriter acknowledges that the Auditor is acceptable to the Underwriter.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.14
<U>FINRA</U>. For a period of 90 days from the later of the Closing Date or the last Option Closing Date, if any, the Company shall advise
the Underwriter (who shall make an appropriate filing with FINRA) if it is or becomes aware that any officer or director of the Company
or any beneficial owner of 10% or more of any class of the Company&rsquo;s securities or equity-linked securities is or becomes an affiliate
or associated person of a FINRA member participating in the Offering (as determined in accordance with the rules and regulations of FINRA).</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.15
<U>No Fiduciary Duties</U>. The Company acknowledges and agrees that the Underwriter&rsquo;s responsibility to the Company is solely contractual
in nature and that none of the Underwriter or its affiliates or any selling agent shall be deemed to be acting in a fiduciary capacity,
or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with the Offering and the other transactions
contemplated by this Agreement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.16
<U>Company Lock-Up Agreements</U>. The Company, on behalf of itself and any successor entity, agrees that, without the prior written consent
of the Underwriter, it will not, for a period of ninety (90) days after the date of this Agreement (the &ldquo;</FONT><FONT STYLE="font-style: normal">Lock-Up
Period<FONT STYLE="font-weight: normal">&rdquo;), (a) offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly
or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares
of capital stock of the Company, (b) file or cause to be filed any registration statement with the Commission relating to the offering
of any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital
stock of the Company or (c) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of capital stock of the Company, whether any such transaction described in <U>clause (a)</U>, <U>(b)</U> or
<U>(c)</U> above is to be settled by delivery of shares of capital stock of the Company or such other securities, in cash or otherwise.
The restrictions contained in this <U>Section 3.16</U> shall not apply to (i)&nbsp;sales of shares of capital stock of the Company under
any trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, existing as of the date of the Underwriting
Agreement, (ii) the Public Securities to be sold hereunder, (iii) the issuance by the Company of shares of capital stock of the Company
upon the exercise of a stock option or warrant or the conversion or vesting of a security outstanding on the date hereof, (iv) the issuance
by the Company of equity awards of the Company under any equity compensation plan of the Company, (v) the issuance by the Company of shares
of capital stock of the Company or securities convertible into, exchangeable for or that represent the right to receive shares of capital
stock of the Company in connection with the acquisition by the Company of the securities, business, technology, property or other assets of another
person or entity <FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">or
(vi) the sale of shares of capital stock of the Company to cover the payment of exercise prices or the payment of taxes associated with
the exercise or vesting of equity awards under any equity compensation plan of the Company.</FONT></FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.17
<U>Release of Lock-up Period</U>. If the Underwriter, in its sole discretion, agrees to release or waive the restrictions set forth in
the Lock-Up Agreements described in <U>Section 2.26</U> for an officer or director of the Company and provide the Company with notice
of the impending release or waiver at least three (3) Business Days before the effective date of the release or waiver, the Company agrees
to announce the impending release or waiver by a press release substantially in the form of <U>Exhibit B</U> hereto through a major news
service at least two (2) Business Days before the effective date of the release or waiver.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.18
<U>Blue Sky Qualifications</U>. The Company shall use commercially reasonable efforts, in cooperation with the Underwriter, if necessary,
to qualify the Public Securities and the Underwriter&rsquo;s Securities for offering and sale under the applicable securities laws of
such states and other jurisdictions (domestic or foreign) as the Underwriter may designate and to maintain such qualifications in effect
so long as required to complete the distribution of the Public Securities; </FONT><FONT STYLE="font-weight: normal">provided, however,
<FONT STYLE="font-style: normal">that the Company shall not be obligated to file any general consent to service of process or to qualify
as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation
in respect of doing business in any jurisdiction in which it is not otherwise so subject.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.19
<U>Reporting Requirements</U>. The Company, during the period when a prospectus relating to the Public Securities is (or, but for the
exception afforded by Rule 172, would be) required to be delivered under the Securities Act, will file all documents required to be filed
with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and Exchange Act Regulations.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.20
<U>Press Releases</U>. Prior to the Closing Date and any Option Closing Date, the Company shall not issue any press release or other communication
directly or indirectly or hold any press conference with respect to the Company, its condition, financial or otherwise, or earnings, business
affairs or business prospects (except for routine oral marketing communications in the ordinary course of business and consistent with
the past practices of the Company and of which the Underwriter is notified), without the prior written consent of the Underwriter, which
consent shall not be unreasonably withheld, unless in the reasonable judgment of the Company and its counsel, and after notification to
the Underwriter, such press release or communication is required by law.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.21
<U>Sarbanes-Oxley</U>. The Company shall use commercially reasonable efforts to comply with all applicable provisions of the Sarbanes-Oxley
Act in effect from time to time.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.22
<U>IRS Forms</U>. The Company shall deliver to the Underwriter (or its agent), prior to or at the Closing Date, a properly completed and
executed Internal Revenue Service (&ldquo;</FONT><FONT STYLE="font-style: normal">IRS<FONT STYLE="font-weight: normal">&rdquo;) Form W-9
or an IRS Form W-8, as appropriate, together with all required attachments to such form.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">4.
<U>Conditions of Underwriter&rsquo;s Obligations</U>. The obligations of the Underwriter to purchase and pay for the Public Securities,
as provided herein, shall be subject to (i) the continuing accuracy of the representations and warranties of the Company as of the date
hereof, as of the Closing Date and each Option Closing Date, as applicable; (ii) the accuracy of the statements of officers of the Company
made pursuant to the provisions hereof; (iii) the performance by the Company of its obligations hereunder; and (iv) the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.1
<U>Regulatory Matters</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.1.1.
<U>Absence of Certain Commission Actions; Required Filings</U>. The Registration Statement is effective under the Securities Act, no
stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued under the
Securities Act, no order preventing or suspending the use of <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal">any
Preliminary Prospectus, the Prospectus or any part thereof shall have been issued and no proceedings for that purpose or pursuant to
Section 8A under the Securities Act shall have been initiated or threatened by the Commission, and all requests for additional information
on the part of the Commission (to be included or incorporated by reference in the Registration Statement or the Prospectus or otherwise)
shall have been complied with to the reasonable satisfaction of the Underwriter. The Prospectus containing the Rule 430A Information
shall have been filed with the Commission in the manner and within the time frame required by Rule 424(b) of the Securities Act Regulations
(without reliance on Rule 424(b)(8)) or a post-effective amendment providing such information shall have been filed with, and declared
effective by, the Commission in accordance with the requirements of Rule 430A under the Securities Act Regulations.</FONT></FONT></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.1.2.
<U>FINRA Clearance</U>. The non-objection letter issued by FINRA with respect to the Registration Statement shall not have been rescinded,
withdrawn or suspended, nor shall FINRA have raised any subsequent objection to, or issued comments with respect to, the amount of compensation
allowable or payable to the Underwriter as described in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.1.3.
<U>NasdaqCM Market Clearance</U>. The Company shall have submitted the Listing of Additional Shares Notification Form to the NasdaqCM
with respect to the Offering of the Public Securities and the NasdaqCM shall not have raised any objection to the submission prior to
the Closing Date or each Option Closing Date, as applicable. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.2
<U>Counsel Matters</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.2.1.
<U>Closing Date Opinion of Counsel to the Company</U>. On the Closing Date and each Option Closing Date, if any, the Underwriter shall
have received (i) the favorable opinion and negative assurance letter of Lucosky Brookman LLP, counsel to the Company (&ldquo;</FONT>Company
Counsel<FONT STYLE="font-weight: normal">&rdquo;), and (ii) the favorable opinion of Schmeiser Olsen &amp; Watts LLP (&ldquo;</FONT>IP
Counsel<FONT STYLE="font-weight: normal">&rdquo;), in each case, dated the Closing Date and each Option Closing Date, as applicable, and
addressed to the Underwriter in form and substance reasonably satisfactory to the Underwriter.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.2.2.
<U>Opinion of Underwriter&rsquo;s Counsel</U>. On the Closing Date and each Option Closing Date, if any, the Underwriter shall have received
from Underwriter&rsquo;s Counsel negative assurance letter of Underwriter&rsquo;s Counsel, dated the Closing Date and each Option Closing
Date, as applicable. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.2.3.
<U>Reliance</U>. In rendering such opinion, Company Counsel and IP Counsel may rely: (i)&nbsp;as to matters involving the application
of laws other than the laws of the United States and jurisdictions in which it is admitted, to the extent such counsel deems proper and
to the extent specified in such opinion, if at all, upon an opinion or opinions (in form and substance reasonably satisfactory to the
Underwriter) of other counsel reasonably acceptable to the Underwriter, familiar with the applicable laws; and (ii)&nbsp;as to matters
of fact, to the extent is deems proper, on certificates or other written statements of officers of the Company and officers of departments
of various jurisdictions having custody of documents respecting the corporate existence or good standing of the Company, provided that
copies of any such statements or certificates shall be delivered to Underwriter&rsquo;s Counsel if requested. The opinions of counsel
referred to in <U>Sections 4.2.1</U> above shall include a statement to the effect that it may be relied upon by Underwriter&rsquo;s Counsel
in its opinion delivered to the Underwriter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.3
<U>Comfort Letters</U>. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.3.1.
<U>Cold Comfort Letter</U>. At the time this Agreement is executed you shall have received a cold comfort letter containing statements
and information of the type customarily included in accountants&rsquo; comfort letters with respect to the financial statements and certain
financial information contained in the Registration Statement,
the Disclosure Package and the Prospectus, addressed to the Underwriter and in form and substance satisfactory in all respects to you
and to the Auditor, dated as of the date of this Agreement<FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">,
from the Auditor.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.3.2.
<U>Bring-down Comfort Letter</U>. At the Closing Date and each Option Closing Date, if any, the Underwriter shall have received from the
Auditor a letter, dated as of the Closing Date or such Option Closing Date, as applicable, to the effect that the Auditor reaffirms the
statements made in the letter furnished pursuant to <U>Section 4.3.1</U>, except that the specified date referred to shall be a date not
more than three (3) Business Days prior to the Closing Date or Option Closing Date, as applicable. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.4
<U>Company Certificates</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.4.1.
<U>Officers&rsquo; Certificate</U>. The Company shall have furnished to the Underwriter a certificate, dated the Closing Date and such
Option Closing Date, as applicable, of its Chief Executive Officer and its Senior Director, Finance stating that (i) such officers have
carefully examined the Registration Statement, the Disclosure Package, any Issuer Free Writing Prospectus and the Prospectus and, in their
opinion, the Registration Statement and each amendment thereto, as of the Applicable Time and as of the Closing Date or such Option Closing
Date, as applicable, did not include any untrue statement of a material fact and did not omit to state a material fact required to be
stated therein or necessary to make the statements therein not misleading, and the Disclosure Package, as of the Applicable Time and as
of the Closing Date and such Option Closing Date, as applicable, any Issuer Free Writing Prospectus as of its date and as of the Closing
Date and such Option Closing Date, as applicable, the Prospectus and each amendment or supplement thereto, as of the respective date thereof
and as of the Closing Date or Option Closing Date, as applicable, did not include any untrue statement of a material fact and did not
omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances in which they were
made, not misleading, (ii) since the date of this Agreement, no event has occurred which should have been set forth in a supplement or
amendment to the Registration Statement, the Disclosure Package or the Prospectus, (iii) to the best of their knowledge after reasonable
investigation, as of the Closing Date or such Option Closing Date, as applicable, the representations and warranties of the Company in
this Agreement are true and correct in all material respects, except for such representations and warranties qualified by materiality
or material adverse change which shall be true and correct in all respects and the Company has complied in all material respects with
all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date or such
Option Closing Date, as applicable, and (iv) there has not been, subsequent to the date of the most recent audited financial statements
included or incorporated by reference in the Disclosure Package, any material adverse change in the financial position or results of operations
of the Company, or any change or development that, singularly or in the aggregate, would involve a material adverse change or a prospective
material adverse change, in or affecting the condition (financial or otherwise), results of operations, business, assets or prospects
of the Company, except as set forth in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.4.2.
<U>Secretary&rsquo;s Certificate</U>. At the Closing Date and each Option Closing Date, if any, the Underwriter shall have received a
certificate of the Company signed by the Secretary of the Company, dated the Closing Date or each Option Closing Date, as applicable,
certifying: (i)&nbsp;that each of the Charter and the Bylaws is true and complete, has not been modified and is in full force and effect;
(ii)&nbsp;that the resolutions of the Company&rsquo;s Board of Directors and/or any committee thereof relating to the Offering are in
full force and effect and have not been modified; (iii) as to the accuracy and completeness of all correspondence between the Company
or Company Counsel and the Commission; and (iv)&nbsp;as to the incumbency of the officers of the Company. The documents referred to in
such certificate shall be attached to such certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.5
<U>No Material Changes</U>. Prior to and on the Closing Date and each Option Closing Date: (i)&nbsp;there shall have been no Material
Adverse Change or development involving a prospective material adverse change in the condition or prospects or the business activities,
financial or otherwise, of the Company from the latest dates as of which such condition is set forth in the Registration Statement, the
Disclosure Package and the Prospectus; (ii)&nbsp;no action, suit or proceeding, at law or in equity, shall have been pending or threatened
against the Company or any <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">Insider before
or by any court or federal or state commission, board or other administrative agency wherein an unfavorable decision, ruling or finding
may materially adversely affect the business, operations, prospects or financial condition or income of the Company, except as set forth
in the Registration Statement, the Disclosure Package and the Prospectus; (iii)&nbsp;no stop order shall have been issued under the Securities
Act and no proceedings therefor shall have been initiated or threatened by the Commission; (iv)&nbsp;no action shall have been taken
and no law, statute, rule, regulation or order shall have been enacted, adopted or issued by any Governmental Entity which would prevent
the issuance or sale of the Public Securities or materially and adversely affect or potentially materially and adversely affect the business
or operations of the Company or the Subsidiary; (v) no injunction, restraining order or order of any other nature by any federal or state
court of competent jurisdiction shall have been issued which would prevent the issuance or sale of the Public Securities or materially
and adversely affect or potentially materially and adversely affect the business or operations of the Company or the Subsidiary; and
(vi) the Registration Statement, the Disclosure Package and the Prospectus and any amendments or supplements thereto shall contain all
material statements which are required to be stated therein in accordance with the Securities Act and the Securities Act Regulations
and shall conform in all material respects to the requirements of the Securities Act and the Securities Act Regulations, and neither
the Registration Statement, the Disclosure Package, the Prospectus nor any Issuer Free Writing Prospectus nor any amendment or supplement
thereto shall contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary
to make the statements therein, in light of the circumstances under which they were made, not misleading.</FONT></FONT></P>




<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.6
<U>Corporate Proceedings</U>. All corporate proceedings and other legal matters incident to the authorization, form and validity of each
of this Agreement, the Public Securities, the Registration Statement, the Disclosure Package, each Issuer Free Writing Prospectus, if
any, and the Prospectus and all other legal matters relating to this Agreement and the transactions contemplated hereby and thereby shall
be reasonably satisfactory in all material respects to Underwriter&rsquo;s Counsel and the Company shall have furnished to such counsel
all documents and information that they may reasonably request to enable them to pass upon such matters.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.7
<U>Delivery of Agreements</U>.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-weight: normal">4.7.1.
On or before the date of this Agreement, the Company shall have delivered to the Underwriter executed copies of the Lock-Up Agreements
from each of the persons listed in <U>Schedule 2</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-weight: normal">4.7.2.
On the Closing Date, the Company shall have delivered to the Underwriter the Firm Shares and the Firm Warrants, and on each Option Closing
Date, if any, the Company shall have delivered to the Underwriter the applicable Option Shares and/or Option Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-weight: normal">4.7.3.
On the Closing Date and each Option Closing Date, if any, the Company shall have delivered to the Underwriter an executed copy or copies
of the Underwriter&rsquo;s Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.8
<U>Representations and Warranties</U>. The representations and warranties of the Company contained herein shall be true and correct on
the date hereof and on and as of the Closing Date or each Option Closing Date, if any, as the case may be; and the statements of the Company
and its officers made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date
or each Option Closing Date, if any, as the case may be.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.9
<U>Additional Documents</U>. At the Closing Date and each Option Closing Date, if any, Underwriter&rsquo;s Counsel shall have been furnished
with such documents and opinions as they may require for the purpose of enabling Underwriter&rsquo;s Counsel to deliver an opinion to
the Underwriter, or in order to evidence the accuracy of any of the representations or warranties, or the fulfilment of any of the conditions,
herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Public Securities as herein
contemplated shall be satisfactory in form and substance to the Underwriter and Underwriter&rsquo;s Counsel.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-weight: normal">5.</FONT> <FONT STYLE="font-weight: normal"><U>Indemnification</U>.</FONT></P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">5.1
<U>Indemnification by the Company</U>. The Company shall indemnify, defend and hold harmless the Underwriter, its affiliates and each
of its and their respective directors, officers, members, employees, representatives and agents and each person, if any, who controls
the Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively the &ldquo;</FONT><FONT STYLE="font-style: normal">Underwriter
Indemnified Parties<FONT STYLE="font-weight: normal">,&rdquo; and each an &ldquo;</FONT>Underwriter Indemnified Party<FONT STYLE="font-weight: normal">&rdquo;)
against any loss, claim, damage, expense or liability whatsoever (or any action, investigation or proceeding in respect thereof), to which
such Underwriter Indemnified Party may become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage, expense,
liability, action, investigation or proceeding arises out of or is based upon (A) any untrue statement or alleged untrue statement of
a material fact contained in any Preliminary Prospectus, the Disclosure Package, any Issuer Free Writing Prospectus, any &ldquo;issuer
information&rdquo; filed or required to be filed pursuant to Rule 433(d) of the Securities Act Regulations, any Registration Statement
or the Prospectus, or in any amendment or supplement thereto or document incorporated by reference therein, (B) the omission or alleged
omission to state in any Preliminary Prospectus, the Disclosure Package, any Issuer Free Writing Prospectus, any &ldquo;issuer information&rdquo;
filed or required to be filed pursuant to Rule 433(d) of the Securities Act Regulations, any Registration Statement or the Prospectus,
or in any amendment or supplement thereto or document incorporated by reference therein, a material fact required to be stated therein
or necessary to make the statements therein not misleading or (C) any breach of the representations and warranties of the Company contained
herein or any certificate delivered pursuant to this Agreement or failure of the Company to perform its obligations hereunder or pursuant
to any law, any act or failure to act, or any alleged act or failure to act, by the Company in connection with, or relating in any manner
to, this Agreement, the Public Securities or the Offering, and which is included as part of or referred to in any loss, claim, damage,
expense, liability, action, investigation or proceeding arising out of or based upon matters covered by <U>subclause (A)</U>, <U>(B)</U>
or <U>(C)</U> above of this <U>Section 5.1</U> (provided&nbsp;that the Company shall not be liable in the case of any matter covered by
this <U>subclause (C)</U> to the extent that it is determined in a final judgment by a court of competent jurisdiction that such loss,
claim, damage, expense or liability resulted directly from any such act or failure to act undertaken or omitted to be taken by the Underwriter
through its gross negligence or willful misconduct), and shall reimburse the Underwriter Indemnified Party promptly upon demand for any
legal fees or other expenses reasonably incurred by that Underwriter Indemnified Party in connection with investigating, or preparing
to defend, or defending against, or appearing as a third party witness in respect of, or otherwise incurred in connection with, any such
loss, claim, damage, expense, liability, action, investigation or proceeding, as such fees and expenses are incurred;&nbsp;</FONT></FONT><FONT STYLE="font-weight: normal"><U>provided</U><FONT STYLE="font-style: normal">,
</FONT><U>however</U><FONT STYLE="font-style: normal">,&nbsp;that the Company shall not be liable in any such case to the extent that
any such loss, claim, damage, expense or liability arises out of or is based upon an untrue statement in, or omission from any Preliminary
Prospectus, the Disclosure Package, any Registration Statement or the Prospectus, or any such amendment or supplement thereto, or any
Issuer Free Writing Prospectus made in reliance upon and in conformity with written information furnished to the Company by or on behalf
of the Underwriter specifically for use therein, which information the parties hereto agree is limited to the Underwriter&rsquo;s Information.
This indemnity agreement is not exclusive and will be in addition to any liability, which the Company might otherwise have and shall not
limit any rights or remedies which may otherwise be available at law or in equity to each Underwriter Indemnified Party.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">5.2
<U>Indemnification by the Underwriter</U>. The Underwriter shall indemnify, defend and hold harmless the Company, the Company&rsquo;s
directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of
Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively the &ldquo;</FONT><FONT STYLE="font-style: normal">Company
Indemnified Parties<FONT STYLE="font-weight: normal">&rdquo; and each a </FONT>&ldquo;Company Indemnified Party<FONT STYLE="font-weight: normal">&rdquo;)
against any loss, claim, damage, expense or liability whatsoever (or any action, investigation or proceeding in respect thereof), to which
such Company Indemnified Party may become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage, expense,
liability, action, investigation or proceeding arises out of or is based upon (i) any untrue statement of a material fact contained in
any Preliminary Prospectus, any Issuer Free Writing Prospectus, any &ldquo;issuer information&rdquo; filed or required to be filed pursuant
to Rule 433(d) of the Securities Act Regulations, any Registration Statement, the Disclosure Package, or the Prospectus, or in any amendment
or supplement thereto, or (ii) the omission to state in any Preliminary Prospectus, any Issuer Free Writing Prospectus, any &ldquo;issuer
information&rdquo; filed or required to be filed pursuant to Rule 433(d) of the Securities Act Regulations, any Registration Statement,
the Disclosure Package, or the Prospectus, or in any amendment or supplement thereto, a material fact required to be stated therein or
necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, but in each case
only to the extent that the untrue statement or omission was made in reliance upon and in conformity with written information furnished
to the Company by or on behalf of the Underwriter specifically for use therein, which information the parties hereto agree is limited
to the Underwriter&rsquo;s Information and shall reimburse the Company Indemnified Parties for any legal or other expenses reasonably
incurred by any Company Indemnified Party in connection with investigating or preparing to defend or defending against or appearing as
third party witness in connection with any such loss, claim, damage, liability, action, investigation or proceeding, as such fees and
expenses are incurred. Notwithstanding the provisions of this <U>Section 5.2</U>, in no event shall any indemnity by the Underwriter under
this <U>Section 5.2</U> exceed the total discount and commission received by the Underwriter in connection with this Offering.</FONT></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">5.3 <U>Procedure</U>.
Promptly after receipt by an indemnified party under this <U>Section 5</U> of notice of the commencement of any action, the
indemnified party shall, if a claim in respect thereof is to be made against an indemnifying party under this <U>Section 5</U>,
notify such indemnifying party in writing of the commencement of that action; </FONT><FONT STYLE="font-weight: normal"><U>provided</U><FONT STYLE="font-style: normal">, </FONT><U>however</U><FONT STYLE="font-style: normal">,
that the failure to notify the indemnifying party shall not relieve it from any liability which it may have under this <U>Section
5</U> except to the extent it has been materially adversely prejudiced by such failure; and, provided, further, that the failure to
notify an indemnifying party shall not relieve it from any liability which it may have to an indemnified party otherwise than under
this <U>Section 5</U>. If any such action shall be brought against an indemnified party, and it shall notify the indemnifying party
thereof, the indemnifying party shall assume the defense of such action with counsel reasonably satisfactory to the indemnified
party (which counsel shall not, except with the written consent of the indemnified party, be counsel to the indemnifying party).
After notice from the indemnifying party to the indemnified party of its assumption of the defense of such action, except as
provided herein, the indemnifying party shall not be liable to the indemnified party under <U>Section 5</U> for any legal or other
expenses subsequently incurred by the indemnified party in connection with the defense of such action other than reasonable costs of
investigation; </FONT><U>provided</U><FONT STYLE="font-style: normal">, </FONT><U>however</U><FONT STYLE="font-style: normal">, that
any indemnified party shall have the right to employ separate counsel in any such action and to participate in the defense of such
action but the fees and expenses of such counsel (other than reasonable costs of investigation) shall be at the expense of such
indemnified party unless (i) the employment thereof has been specifically authorized in writing by the Company in the case of a
claim for indemnification under <U>Section 5.1</U> or the Underwriter in the case of a claim for indemnification under <U>Section
5.2</U>, (ii) such indemnified party shall have been advised by its counsel that there may be one or more legal defenses available
to it which are different from or additional to those available to the indemnifying party, or (iii) the indemnifying party has
failed to assume the defense of such action and employ counsel reasonably satisfactory to the indemnified party within a reasonable
period of time after notice of the commencement of the action or the indemnifying party does not diligently defend the action after
assumption of the defense, in which case, if such indemnified party notifies the indemnifying party in writing that it elects to
employ separate counsel at the expense of the indemnifying party, the indemnifying party shall
not have the right to assume the defense of (or, in the case of a failure to diligently defend the action after assumption of the defense,
to continue to defend) such action on behalf of such indemnified party and the indemnifying party shall be responsible for legal or other
expenses subsequently incurred by such indemnified party in connection with the defense of such action; <FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"><U>provided</U><FONT STYLE="font-style: normal">,
</FONT><U>however</U><FONT STYLE="font-style: normal">, that the indemnifying party shall not, in connection with any one such action
or separate but substantially similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances,
be liable for the reasonable fees and expenses of more than one separate firm of attorneys at any time any such indemnified party (in
addition to any local counsel), which firm shall be designated in writing by the Underwriter if the indemnified party under this <U>Section
5</U> is an Underwriter Indemnified Party or by the Company if an indemnified party under this <U>Section 5</U> is a Company Indemnified
Party. Subject to this <U>Section 5.3</U>, the amount payable by an indemnifying party under <U>Section 5</U> shall include, but not be
limited to, (x) reasonable legal fees and expenses of counsel to the indemnified party and any other expenses in investigating, or preparing
to defend or defending against, or appearing as a third party witness in respect of, or otherwise incurred in connection with, any action,
investigation, proceeding or claim, and (y) all amounts paid in settlement of any of the foregoing. No indemnifying party shall, without
the prior written consent of the indemnified parties, settle or compromise or consent to the entry of judgment with respect to any pending
or threatened action or any claim whatsoever, in respect of which indemnification or contribution could be sought under this <U>Section
5</U> (whether or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent
(i) includes an unconditional release of each indemnified party in form and substance reasonably satisfactory to such indemnified party
from all liability arising out of such action or claim and (ii) does not include a statement as to or an admission of fault, culpability
or a failure to act by or on behalf of any indemnified party. Subject to the provisions of the following sentence, no indemnifying party
shall be liable for settlement of any pending or threatened action or any claim whatsoever that is effected without its written consent
(which consent shall not be unreasonably withheld or delayed), but if settled with its written consent, if its consent has been unreasonably
withheld or delayed or if there be a judgment for the plaintiff in any such matter, the indemnifying party agrees to indemnify and hold
harmless any indemnified party from and against any loss or liability by reason of such settlement or judgment. In addition, if at any
time an indemnified party shall have requested that an indemnifying party reimburse the indemnified party for fees and expenses of counsel,
such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated herein effected without its written
consent if (i) such settlement is entered into more than forty-five (45) days after receipt by such indemnifying party of the request
for reimbursement, (ii) such indemnifying party shall have received notice of the terms of such settlement at least thirty (30) days prior
to such settlement being entered into and (iii) such indemnifying party shall not have reimbursed such indemnified party in accordance
with such request prior to the date of such settlement.</FONT></FONT></FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">5.4
<U>Contribution</U>. If the indemnification provided for in this <U>Section 5</U> is unavailable or insufficient to hold harmless an
indemnified party under <U>Section 5.1</U> or <U>Section 5.2</U>, then each indemnifying party shall, in lieu of indemnifying such indemnified
party, contribute to the amount paid, payable or otherwise incurred by such indemnified party as a result of such loss, claim, damage,
expense or liability (or any action, investigation or proceeding in respect thereof), as incurred, (i) in such proportion as shall be
appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriter on the other hand from the Offering,
or (ii) if the allocation provided by <U>clause (i)</U> of this <U>Section 5.4</U> is not permitted by applicable law, in such proportion
as is appropriate to reflect not only the relative benefits referred to in <U>clause (i)</U> of this <U>Section 5.4</U> but also the
relative fault of the Company on the one hand and the Underwriter on the other with respect to the statements, omissions, acts or failures
to act which resulted in such loss, claim, damage, expense or liability (or any action, investigation or proceeding in respect thereof)
as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriter
on the other with respect to such offering shall be deemed to be in the same proportion as the total proceeds from the Offering purchased
under this Agreement (before deducting expenses) received by the Company bear to the total underwriting discount and commissions received
by the Underwriter in connection with the Offering, in each case as set forth in the table on the cover page of the Prospectus. The relative
fault of the Company on the one hand and the Underwriter on the other shall be determined by reference to, among other things, whether
the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information
supplied by the Company on the one hand or the Underwriter on the other, the intent of the parties and their relative knowledge, access
to information and opportunity to correct or prevent such untrue statement, omission, act or failure to act; provided that the parties
hereto agree that the written information furnished to the Company by or on behalf of <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal">the
Underwriter for use in any Preliminary Prospectus, any Registration Statement, the Disclosure Package or the Prospectus, or in any amendment
or supplement thereto, consists solely of the Underwriter&rsquo;s Information. The Company and the Underwriter agree that it would not
be just and equitable if contributions pursuant to this <U>Section 5.4</U> be determined by pro rata allocation or by any other method
of allocation that does not take into account the equitable considerations referred to herein. The amount paid or payable by an indemnified
party as a result of the loss, claim, damage, expense, liability, action, investigation or proceeding referred to above in this <U>Section
5.4</U> shall be deemed to include, for purposes of this <U>Section 5.4</U>, any legal or other expenses reasonably incurred by such
indemnified party in connection with investigating, preparing to defend or defending against or appearing as a third party witness in
respect of, or otherwise incurred in connection with, any such loss, claim, damage, expense, liability, action, investigation or proceeding.
Notwithstanding the provisions of this <U>Section 5.4</U>, the Underwriter shall not be required to contribute any amount in excess of
the total discount and commission received by the Underwriter in connection with the Offering less the amount of any damages which the
Underwriter has otherwise paid or become liable to pay by reason of any untrue or alleged untrue statement, omission or alleged omission,
act or alleged act or failure to act or alleged failure to act. No person guilty of fraudulent misrepresentation (within the meaning
of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
</FONT></FONT></P>




<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-weight: normal">6.</FONT> <FONT STYLE="font-weight: normal"><U>Additional Covenants</U>.</FONT></P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">6.1
<U>Board Composition and Board Designations</U>. The Company shall ensure that: (i)&nbsp;the qualifications of the persons serving as
members of the Board of Directors and the overall composition of the Board of Directors comply with the Sarbanes-Oxley Act, the Exchange
Act and the listing rules of the NasdaqCM or any other national securities exchange, as the case may be, in the event the Company seeks
to have its Common Stock listed on another exchange or quoted on an automated quotation system, subject to any applicable cure period,
and (ii)&nbsp;if applicable, at least one member of the Audit Committee of the Board of Directors qualifies as an &ldquo;audit committee
financial expert,&rdquo; as such term is defined under Regulation S-K and the listing rules of the NasdaqCM.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">6.2
<U>Prohibition on Press Releases and Public Announcements</U>. Prior to the last Option Closing Date, if any, the Company shall not issue
any press release or other communication directly or indirectly or hold any press conference with respect to the Company, its condition,
financial or otherwise, or earnings, business affairs or business prospects (except for routine oral marketing communications in the ordinary
course of business and consistent with the past practices of the Company and of which the Underwriter is notified), without the prior
written consent of the Underwriter (not to be withheld unreasonably), unless in the judgment of the Company and its counsel, and after
notification to the Underwriter, such press release or communication is required by law or applicable NasdaqCM rules.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-weight: normal">7.</FONT> <FONT STYLE="font-weight: normal"><U>Effective Date of this Agreement and Termination Thereof</U>.</FONT></P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">7.1
<U>Effective Date</U>. This Agreement shall become effective when both the Company and the Underwriter have executed the same and delivered
counterparts of such signatures to the other party.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">7.2
<U>Termination</U>. The Underwriter shall have the right to terminate this Agreement at any time prior to the Closing Date, (i)&nbsp;if
any domestic or international event or act or occurrence has materially disrupted, or in your opinion will in the immediate future materially
disrupt, general securities markets in the United States; or (ii)&nbsp;if
trading on the New York Stock Exchange or <FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Nasdaq
Stock Market LLC shall have been suspended or materially limited, or minimum or maximum prices for trading shall have been fixed, or maximum
ranges for prices for securities shall have been required by FINRA or by order of the Commission or any other government authority having
jurisdiction; or (iii)&nbsp;if the United States shall have become involved in a new war or an increase in major hostilities; or (iv)&nbsp;if
a banking moratorium has been declared by a New York State or federal authority; or (v)&nbsp;if a moratorium on foreign exchange trading
has been declared which materially adversely impacts the United States securities markets; or (vi)&nbsp;if the Company shall have sustained
a material loss by fire, flood, accident, hurricane, earthquake, theft, sabotage or other calamity or malicious act which, whether or
not such loss shall have been insured, will, in your opinion, make it inadvisable to proceed with the delivery of the Firm Units or the
Option Securities; or (vii)&nbsp;if the Company is in material breach of any of its representations, warranties or covenants hereunder;
or (viii)&nbsp;if the Underwriter shall have become aware after the date hereof of such a material adverse change in the conditions or
prospects of the Company, or such adverse material change in general market conditions as in the Underwriter&rsquo;s judgment would make
it impracticable to proceed with the offering, sale and/or delivery of the Public Securities or to enforce contracts made by the Underwriter
for the sale of the Public Securities.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">7.3
<U>Expenses</U>. Notwithstanding anything to the contrary in this Agreement, in the event that this Agreement shall not be carried out
for any reason whatsoever, within the time specified herein or any extensions thereof pursuant to the terms herein, the Company shall
be obligated to pay to the Underwriter its reasonable accountable out-of-pocket expenses actually incurred related to the transactions
contemplated herein then due and payable (including the fees and disbursements of Underwriter&rsquo;s Counsel) up to $75,000 and upon
demand the Company shall pay the full amount thereof to the Underwriter on behalf of the Underwriter; </FONT><FONT STYLE="font-weight: normal">provided,
however, <FONT STYLE="font-style: normal">that such expense cap in no way limits or impairs the indemnification and contribution provisions
of this Agreement. Notwithstanding the foregoing, any advance received by the Underwriter will be reimbursed to the Company to the extent
not actually incurred in compliance with FINRA Rule 5110(g)(4).</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">7.4
<U>Survival of Indemnification</U>. Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any
termination of this Agreement, and whether or not this Agreement is otherwise carried out, the provisions of <U>Section 5</U> shall remain
in full force and effect and shall not be in any way affected by, such election or termination or failure to carry out the terms of this
Agreement or any part hereof.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">7.5
<U>Representations, Warranties, Agreements to Survive</U>. All representations, warranties and agreements contained in this Agreement
or in certificates of officers of the Company submitted pursuant hereto, shall remain operative and in full force and effect regardless
of (i)&nbsp;any investigation made by or on behalf of the Underwriter or its affiliates or selling agents, any person controlling the
Underwriter, its officers or directors or any person controlling the Company or (ii)&nbsp;delivery of and payment for the Public Securities.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-weight: normal">8.</FONT> <FONT STYLE="font-weight: normal"><U>Miscellaneous</U>.</FONT></P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.1
<U>Notices</U>. All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall be mailed
(registered or certified mail, return receipt requested), personally delivered or sent by facsimile transmission and confirmed and shall
be deemed given when so delivered or faxed and confirmed or if mailed, two (2) days after such mailing.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If to the Underwriter:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Newbridge Securities Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1200 North Federal Highway, Suite 400</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Boca Raton, Florida 33432</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 1in">Attn:</TD><TD>Chad D. Champion, Senior Managing Director</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Email: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Tel. No: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><BR>
McGuireWoods LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">1251 Avenue of the Americas, 20<SUP>th</SUP> Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">New York, NY 10020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 1in; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen Older, Esq.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David S. Wolpa, Esq.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Email:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Modular Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">10740 Thornmint Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">San Diego, CA 92127</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attention: James Besser</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Email:  </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Tel. No: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Lucosky Brookman LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">101 Wood Avenue South</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Woodbridge, NJ 08830</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attention:  Lawrence Metelitsa</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Email: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Tel. No: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.2
<U>Headings</U>. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or
affect the meaning or interpretation of any of the terms or provisions of this Agreement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.3
<U>Absence of Fiduciary Relationship</U>. The Company acknowledges and agrees that:</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i) the Underwriter&rsquo;s
responsibility to the Company is solely contractual in nature, the Underwriter has been retained solely to act as an underwriter in connection
with the Offering and no fiduciary, advisory or agency relationship between the Company and the Underwriter has been created in respect
of any of the transactions contemplated by this Agreement, irrespective of whether either the Underwriter has advised or is advising the
Company on other matters;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 103.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii) the price of the Public
Securities set forth in this Agreement was established by the Company following discussions and arms-length negotiations with the Underwriter,
and the Company is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions
contemplated by this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 103.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii) it has been advised
that the Underwriter and its respective affiliates are engaged in a broad range of transactions which may involve interests that differ
from those of the Company and that the Underwriter has no obligation to disclose such interests and transactions to the Company by virtue
of any fiduciary, advisory or agency relationship.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.4
<U>Research Analyst Independence</U>. The Company acknowledges that the Underwriter&rsquo;s research analysts and research departments
are required to be independent from its investment banking division and are subject to certain regulations and internal policies, and
that the Underwriter&rsquo;s research analysts may hold views and make statements or investment recommendations and/or publish research
reports with respect to the Company and/or the offering that differ from the views of their investment banking division. The Company acknowledges
that the Underwriter is a full service securities firm and as such from time to time, subject to applicable securities laws, rules and
regulations, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity
securities of the Company; provided, however, that nothing in this <U>Section 8.4</U> shall relieve the Underwriter of any responsibility
or liability it may otherwise bear in connection with activities in violation of applicable securities laws, rules or regulations.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.5
<U>Amendment</U>. This Agreement may only be amended by a written instrument executed by each of the parties hereto.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.6
<U>Entire Agreement</U>. This Agreement (together with the other agreements and documents being delivered pursuant to or in connection
with this Agreement) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof and thereof, and
supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.7
<U>Binding Effect</U>. This Agreement shall inure solely to the benefit of and shall be binding upon the Underwriter, the Company and
the controlling persons, directors and officers referred to in <U>Section 5</U>, and their respective successors, legal representative,
heirs and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy or claim under or in respect
of or by virtue of this Agreement or any provisions herein contained. The term &ldquo;successors and assigns&rdquo; shall not include
a purchaser, in its capacity as such, of securities from the Underwriter.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.8
<U>Governing Law; Consent to Jurisdiction; Trial by Jury</U>. This Agreement shall be governed by and construed and enforced in accordance
with the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby agrees that any
action, proceeding or claim against it arising out of, or relating in any way to this Agreement shall be brought and enforced in state
and federal courts located in the Borough of Manhattan in the City of New York, and irrevocably submits to such jurisdiction, which jurisdiction
shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient
forum. Any such process or summons to be served upon the Company may be served by transmitting a copy thereof by registered or certified
mail, return receipt requested, postage prepaid, addressed to it at the address set forth in <U>Section 9.1</U>. Such mailing shall be
deemed personal service and shall be legal and binding upon the Company in any action, proceeding or claim. The Company agrees that the
prevailing party(ies) in any such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys&rsquo;
fees and expenses relating to such action or proceeding and/or incurred in connection with the preparation therefor. The Company (on its
behalf and, to the extent permitted by applicable law, on behalf of its shareholders and affiliates) and the Underwriter hereby irrevocably
waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or
relating to this Agreement or the transactions contemplated hereby.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.9 <U>Execution
in Counterparts</U>. This Agreement may be executed in one or more counterparts, and by the different parties hereto in separate
counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and the same
agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered to
each of the other parties hereto. Delivery of
a signed counterpart of this Agreement by facsimile or email/pdf transmission shall constitute valid and sufficient delivery thereof.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.10
<U>Waiver, etc</U>. The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall not
be deemed or construed to be a waiver of any such provision, nor to in any way effect the validity of this Agreement or any provision
hereof or the right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No waiver of any breach,
non-compliance or non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth in a written instrument
executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of any such breach, non-compliance
or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[Signature Page Follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">If
the foregoing correctly sets forth the understanding between the Underwriter and the Company, please so indicate in the space provided
below for that purpose, whereupon this letter shall constitute a binding agreement between us.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt; text-transform: uppercase">MODULAR MEDICAL, </FONT><FONT STYLE="font-size: 10pt">INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">James Besser, Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">Confirmed as of the date first written above mentioned:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">NEWBRIDGE SECURITIES CORPORATION</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-size: 10pt">Chad D. Champion</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Senior Managing Director</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">[Signature
Page]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Modular
Medical, Inc. &ndash; Underwriting Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 1-A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Pricing Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 36; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch. <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-A</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 1-B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Issuer General Use Free Writing Prospectuses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch. 1-B-1 </P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>List of Lock-Up Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 38; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch. 2-1</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Warrant</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(See attached.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 39; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-1</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Lock-Up Agreement<BR>
<BR>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">________________, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Newbridge Securities Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1200 North Federal Highway, Suite 400</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boca Raton, Florida 33432</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned understands
that Newbridge Securities Corporation (the &ldquo;<B>Underwriter</B>&rdquo;) proposes to enter into an Underwriting Agreement (the &ldquo;<B>Underwriting
Agreement</B>&rdquo;) with Modular Medical, Inc., a Nevada corporation (the &ldquo;<B>Company</B>&rdquo;), providing for the public offering
(the &ldquo;<B>Public Offering</B>&rdquo;) of shares of Common Stock, par value $0.001 per share (the &ldquo;<B>Shares</B>&rdquo;), and
warrants of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To induce the Underwriter
to continue its efforts in connection with the Public Offering, the undersigned hereby agrees that, without the prior written consent
of the Underwriter, the undersigned will not, during the period commencing on the date hereof and ending ninety (90) days after the date
of the final prospectus (the &ldquo;<B>Prospectus</B>&rdquo;) relating to the Public Offering (the &ldquo;<B>Lock-Up Period</B>&rdquo;),
(1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any
option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of capital stock of
the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company, whether now
owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition
(collectively, the &ldquo;<B>Lock-Up Securities</B>&rdquo;); (2) enter into any swap or other arrangement that transfers to another, in
whole or in part, any of the economic consequences of ownership of Lock-Up Securities, whether any such transaction is to be settled by
delivery of shares of Lock-Up Securities, in cash or otherwise; (3) make any demand for or exercise any right with respect to the registration
of any Lock-Up Securities; or (4) publicly disclose the intention to make any offer, sale, pledge or disposition, or to enter into any
transaction, swap, hedge or other arrangement relating to any Lock-Up Securities. Notwithstanding the foregoing, and subject to the conditions
below, the undersigned may transfer Lock-Up Securities without the prior written consent of the Underwriter in connection with (a) transactions
relating to Lock-Up Securities acquired in open market transactions after the completion of the Public Offering; <I>provided</I> that
no filing under Section&nbsp;16(a) of the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;), shall be
required or shall be voluntarily made in connection with subsequent sales of Lock-Up Securities acquired in such open market transactions;
(b) transfers of Lock-Up Securities as a <I>bona fide</I> gift, by will or intestacy or to a family member or trust for the benefit of
a family member (for purposes of this lock-up agreement, &ldquo;family member&rdquo; means any relationship by blood, marriage or adoption,
not more remote than first cousin); (c) transfers of Lock-Up Securities to a charity or educational institution; (d) if the undersigned,
directly or indirectly, controls a corporation, partnership, limited liability company or other business entity, any transfers of Lock-Up
Securities to any shareholder, partner or member of, or owner of similar equity interests in, the undersigned, as the case may be, or
(e) the sales of Shares to cover the payment of the exercise prices or the payment of taxes associated with the exercise or vesting of
equity awards under any equity compensation plan of the Company; <I>provided</I> that in the case of any transfer pursuant to the foregoing
<U>clauses&nbsp;(b)</U>, <U>(c)</U> or <U>(d)</U>, (i) any such transfer shall not involve a disposition for value, (ii) each transferee
shall sign and deliver to the Underwriter a lock-up agreement substantially in the form of this lock-up agreement and (iii) no filing
under Section&nbsp;16(a) of the Exchange Act shall be required or shall be voluntarily made, except for a Form 5. The undersigned also
agrees and consents to the entry of stop transfer instructions with the Company&rsquo;s transfer agent and registrar against the transfer
of the undersigned&rsquo;s Lock-Up Securities except in compliance with this lock-up agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the undersigned is an officer
or director of the Company, (i) the undersigned agrees that the foregoing restrictions shall be equally applicable to any issuer-directed
or &ldquo;friends and family&rdquo; Shares that the undersigned may purchase in the Public Offering; (ii) the Underwriter agrees that,
at least three (3) Business Days (as that term is defined in the Underwriting Agreement) before the effective date of any release or waiver
of the foregoing restrictions in connection with a transfer of Lock-Up Securities, the Underwriter will notify the Company of the impending
release or waiver; and (iii) the Company has agreed in the Underwriting Agreement to announce the impending release or waiver by press
release through a major news service at least two (2) Business Days before the effective date of the release or waiver. Any release or
waiver granted by the Underwriter hereunder to any such officer or director shall only be effective two (2) Business Days after the publication
date of such press release. The provisions of this paragraph will not apply if (a) the release or waiver is effected solely to permit
a transfer of Lock-Up Securities not for consideration and (b) the transferee has agreed in writing to be bound by the same terms described
in this lock-up agreement to the extent and for the duration that such terms remain in effect at the time of such transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. B-1</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No provision in this agreement
shall be deemed to restrict or prohibit the exercise, exchange or conversion by the undersigned of any securities exercisable or exchangeable
for or convertible into Shares, as applicable; <I>provided</I> that the undersigned does not transfer the Public Securities (as that term
is defined in the Underwriting Agreement) acquired on such exercise, exchange or conversion during the Lock-Up Period, unless otherwise
permitted pursuant to the terms of this lock-up agreement. In addition, no provision herein shall be deemed to restrict or prohibit the
entry into or modification of a so-called &ldquo;10b5-1&rdquo; plan at any time (other than the entry into or modification of such a plan
in such a manner as to cause the sale of any Lock-Up Securities within the Lock-Up Period).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned understands
that the Company and the Underwriter are relying upon this lock-up agreement in proceeding toward consummation of the Public Offering.
The undersigned further understands that this lock-up agreement is irrevocable and shall be binding upon the undersigned&rsquo;s heirs,
legal representative, successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned understands
that, if the Underwriting Agreement is not executed by July 31, 2023, or if the Underwriting Agreement (other than the provisions thereof
which survive termination) shall terminate or be terminated prior to payment for and delivery of the Public Securities to be sold thereunder,
then this lock-up agreement shall be void and of no further force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whether or not the Public
Offering actually occurs depends on a number of factors, including market conditions. Any Public Offering will only be made pursuant to
an Underwriting Agreement, the terms of which are subject to negotiation between the Company and the Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Very truly yours,</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">(Name - Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">(Signature)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">(Name of Signatory, in the case of entities - Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">(Title of Signatory, in the case of entities - Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: justify">Address:</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U></U></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Press Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>MODULAR
MEDICAL,</B></FONT><B> INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><BR>
[Date]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Modular Medical, Inc. (the &ldquo;Company&rdquo;)
announced today that Newbridge Securities Corporation acting as Underwriter for the Company&rsquo;s recent public offering of&nbsp;____
shares of the Company&rsquo;s Common Stock, is [waiving] [releasing] a lock-up restriction with respect to _________&nbsp; shares of the
Company&rsquo;s Common Stock held by [certain officers or directors] [an officer or director] of the Company.&nbsp; The [waiver] [release]
will take effect on&nbsp; _________, 20___, and the shares may be sold on or after such date.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This press release is not an offer or sale
of the securities in the United States or in any other jurisdiction where such offer or sale is prohibited, and such securities may not
be offered or sold in the United States absent registration or an exemption from registration under the Securities Act of 1933, as amended.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Form of Underwriter&rsquo;s Warrant</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I><U>(See attached.)</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Ex. C-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 222.3pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 222.3pt"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ea178793ex5-1_modular.htm
<DESCRIPTION>OPINION OF LUCOSKY BROOKMAN LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"></P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 70%; padding: 0.25pt; font-size: 10pt"><IMG SRC="ex5-1_001.jpg" ALT=""></TD>
    <TD STYLE="vertical-align: bottom; width: 30%; padding: 0.25pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt"><B>LUCOSKY BROOKMAN LLP</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">May 17, 2023</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 5.75pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">101 Wood Avenue South</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">5th floor</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Woodbridge, NJ 08830</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">T - (732) 395-4400</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">F - (732) 395-4401</P></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Modular Medical, Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10740 Thornmint Road</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Diego, California 92127</P></TD>
    <TD STYLE="vertical-align: top; padding: 3.25pt 0.25pt 0.25pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">111 Broadway</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Suite 807</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">New York, NY 10006</P></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">T - (212) 332-8160</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">F - (212) 332-8161</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 0.25pt"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.75pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 3.25pt 0.25pt 0.25pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">www.lucbro.com</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 46px; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 46px; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Re:</B></FONT></TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Registration Statement on Form S-1 (File No. 333-271413)</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have acted as counsel to you, Modular Medical,
Inc., a Nevada corporation (the &ldquo;Company&rdquo;), in connection with the Company&rsquo;s Registration Statement on Form S-1 filed
with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) pursuant to the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;) (File No. 333-271413) (the &ldquo;Registration Statement&rdquo;) with respect to (i) 4,408,450 Units (the &ldquo;Units&rdquo;),
with each Unit consisting of two shares of the Company&rsquo;s common stock, $0.001 par value per share (the &ldquo;Common Stock&rdquo;),
and one warrant to purchase one share of Common Stock (the &ldquo;Warrant&rdquo;) at an exercise price equal to 120% of the public offering
price of the Units; (ii) up to 4,408,450 shares of Common Stock issuable upon exercise of the Warrants (the &ldquo;Warrant Shares&rdquo;);
(iii) up to 1,322,534 shares of Common Stock, purchased pursuant to over allotments, if any (the &ldquo;Over Allotment Shares&rdquo;);
(iv) up to 317,460 Warrants to purchase 661,267 shares of Common Stock, issued pursuant to over-allotments, if any (the &ldquo;Over-Allotment
Warrants&rdquo;); (v) up to 661,267 shares of Common Stock underlying the Over-Allotment Warrants (the &ldquo;Underlying Over-Allotment
Warrant Shares&rdquo;); (vi) up to 617,183 warrants to purchase 617,183 shares of Common Stock, issued to the representative of the underwriter
(the &ldquo;Representative Warrants&rdquo;); and (vii) up to 617,183 shares of Common Stock underlying the Representative Warrants (the
&ldquo;Representative Warrant Shares&rdquo;). This opinion is being furnished in accordance with the requirements of Item 601(b)(5) of
Regulation S-K under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with this opinion, we have examined
the originals or copies certified or otherwise identified to our satisfaction of the following: (a) Articles of Incorporation of the Company,
as amended to date, (b) Bylaws of the Company, as amended to date, and (c) the Registration Statement and all exhibits thereto. In addition
to the foregoing, we also have relied as to matters of fact upon the representations made by the Company and its representatives and we
have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, and the conformity to
original documents of all documents submitted to us certified or photostatic copies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based upon the foregoing and in reliance thereon,
and subject to the qualifications, limitations, exceptions and assumptions set forth herein, we are of the opinion that: (i) the shares
of Common Stock included in the Units, when issued against payment therefor as set forth in the Registration Statement, will be validly
issued, fully paid and non-assessable; (ii) the Warrants included in the Units, when issued as set forth in the Registration Statement,
will be legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms; (iii) the
Warrant Shares, when issued upon exercise of the Warrants against payment therefor as set forth in the Registration Statement, will be
validly issued, fully paid and non-assessable; (iv) the Units, when issued against payment thereof as set forth in the Registration Statement,
will be validly issued, fully paid and non-assessable, and will be legal, valid and binding obligations of the Company, enforceable against
the Company in accordance with their terms; (v) the Over-Allotment Shares, when issued against payment therefor as set forth in the Registration
Statement, will be validly issued, fully paid and non-assessable; (vi) the Over-Allotment Warrants, when issued as set forth in the Registration
Statement, will be legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms;
(vii) the Underlying Over-Allotment Warrant Shares when issued upon exercise of the Over-Allotment Warrants against payment therefor as
set forth in the Registration Statement will be validly issued, fully paid and non-assessable; (viii) the Representative Warrants, when
issued as set forth in the Registration Statement, will be legal, valid and binding obligations of the Company, enforceable against the
Company in accordance with their terms; and (ix) the Underlying Representative Warrant Shares when issued upon exercise of the Representative
Warrants against payment therefor as set forth in the Registration Statement will be validly issued, fully paid and non-assessable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our opinion is limited to the federal laws of
the United States and Chapter 78 of the Nevada Revised Statutes. We express no opinion as to the effect of the law of any other jurisdiction.
Our opinion is rendered as of the date hereof, and we assume no obligation to advise you of changes in law or fact (or the effect thereof
on the opinions expressed herein) that hereafter may come to our attention. This opinion letter is limited to the laws in effect as of
the date the Registration Statement is declared effective by the Commission and is provided exclusively in connection with the public
offering contemplated by the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This opinion letter speaks only as of the date
hereof and we assume no obligation to update or supplement this opinion letter if any applicable laws change after the date of this opinion
letter or if we become aware after the date of this opinion letter of any facts, whether existing before or arising after the date hereof,
that might change the opinions expressed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This opinion letter is furnished in connection
with the filing of the Registration Statement and may not be relied upon for any other purpose without our prior writ ten consent in each
instance. Further, no portion of this letter may be quoted, circulated or referred to in any other document for any other purpose without
our prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the filing of this opinion
with the Commission as an exhibit to the Registration Statement and to the use of our name as it appears in the Prospectus included in
the Registration Statement. In giving such consent, we do not thereby admit that we come within the category of persons whose consent
is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder. This opinion
is expressed as of the date hereof unless otherwise expressly stated, and we disclaim any undertaking to advise you of any subsequent
changes in the facts stated or assumed herein or of any subsequent changes in applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 60%; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 40%; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Very Truly Yours,</FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.75pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>/s/ Lucosky Brookman LLP</I></FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Lucosky Brookman LLP</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>ea178793ex99-1_modular.htm
<DESCRIPTION>PRESS RELEASE DATED MAY 16, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Modular Medical Announces Pricing of Upsized
$9.4 Million Public Offering </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SAN
DIEGO, CA</B></FONT><B>&nbsp;/ ACCESSWIRE /&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">May 16, 2023</FONT>&nbsp;/&nbsp;</B><FONT STYLE="font-family: Times New Roman, Times, Serif">Modular
Medical, Inc.&nbsp;(the &ldquo;Company&rdquo; or &ldquo;Modular Medical&rdquo;) (Nasdaq: MODD), a development stage insulin delivery technology
company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced the pricing of an
upsized underwritten public offering of 8,816,900 shares of its common stock and warrants to purchase 4,408,450 shares of its common stock.
The securities are being sold as a unit, with each unit comprising two shares of common stock and one warrant to purchase one share of
common stock. The units are being sold at a combined price to the public of&nbsp;$2.13&nbsp;per unit, yielding an effective price of $1.06
per share and $0.01 per warrant. The warrants will be exercisable at&nbsp;$1.22&nbsp;per share and will expire five years from the date
of issuance.&nbsp;The Company&nbsp;has granted the underwriter a 30-day option to purchase up to an additional 1,322,534 shares and an
additional 661,267 warrants to cover over-allotments, if any. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Newbridge Securities Corporation is acting as
the sole book-running manager of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net proceeds from the offering are expected to
be approximately $8.3 million after deducting underwriting discounts and commissions and estimated offering expenses. Modular Medical
intends to use the net proceeds from this offering for general corporate purposes, including working capital, to fund its operations through
the approval of its product by the FDA, to develop its initial sales and marketing infrastructure, to fund additional research and development
activities, to develop initial manufacturing and production capabilities and make related capital expenditures. The offering is expected
to close on or about May 18, 2023, subject to the satisfaction of customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A registration statement on Form S-1 (File No.
333-271413) was filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) and became effective on May 15, 2023. A final prospectus
relating to the offering will be filed with the SEC. Electronic copies of the final prospectus relating to the offering may be obtained,
when available, on the SEC&rsquo;s website at http://www.sec.gov or by contacting Newbridge Securities Corporation, Attn: Equity Syndicate
Department, 1200 North Federal Highway, Suite 400, Boca Raton, FL 33432, by email at syndicate@newbridgesecurities.com or by telephone
at (877) 447-9625.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release does not constitute an offer
to sell or the solicitation of an offer to buy, nor are there any sales of these securities in any jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Modular Medical</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Modular Medical, Inc. (Nasdaq: MODD) is a development-stage
medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the
company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and
simple to learn. Our mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond
&ldquo;superusers&rdquo; and providing &ldquo;diabetes care for the rest of us.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Modular Medical
was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding MODD, Mr. DiPerna was
the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at&nbsp;https://modular-medical.com</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains forward-looking statements
that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements
are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statements
contained in this press release. These factors include, but are not limited to, market and other conditions, risks related to the completion
of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of net proceeds from the
offering, whether the Company can successfully develop the Company&rsquo;s proprietary technologies and whether the market will accept
the Company&rsquo;s products and services, and the impact of COVID-19, general economic, industry or political conditions in the United
States or internationally as well as other risk factors and business considerations described in the Company&rsquo;s SEC filings, including
its annual report on Form 10-K. Any forward-looking statements in this press release should be evaluated in light of these important risk
factors. In addition, any forward-looking statements included in this press release represent the Company&rsquo;s views only as of the
date of its publication and should not be relied upon as representing its views as of any subsequent date. The Company assumes no obligation
to update these forward-looking statements, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All trademarks mentioned herein are the property
of their respective owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>CONTACT: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Jeb Besser</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Modular Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+1 (617) 399-1741</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IR@modular-medical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SOURCE:&nbsp;</B>Modular Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  Q .D# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#TKXA^.9/
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MQ!^)WB&U:YTG2+.[A1MC/';CAL9QR:T-,^+/B;1_$L&E>+](BMTF=58I&49
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MPK?T?XO:QI.MII/C?2A:,Q"^>B%"F>A*]"ON*[[QGXWTSP?H:7]Q_I#W'%M
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M)V5AG$74L?Q+^)U_>@F71M,LWD3TPJDC\V/Z5<^ ]Y#867B.]N&"10QI(Y]
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L "_TH/WOPHHH 7^(TM%% #.[?C3A_2BB@ /0TUON_@:** ''[M+110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !( 'H# 2(  A$! Q$!_\0
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7^]]3:3?Y:^9MWX^;;TS[4ZBBLCI/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>modd-20230515.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qpZs7xRiXgen8uBYXYsWamICaPtyJ1x+YkxuG9/fWl6LyUuN7wexy6vmpm2oXYP -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:MODD="http://modular-medical.com/20230515" elementFormDefault="qualified" targetNamespace="http://modular-medical.com/20230515">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://modular-medical.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="modd-20230515_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="modd-20230515_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>modd-20230515_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>modd-20230515_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://modular-medical.com/role/Cover" xlink:href="modd-20230515.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://modular-medical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139797948498192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 15, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 15,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MODULAR MEDICAL, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001074871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0620495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10740 Thornmint Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">800-3500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MODD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>ea178793-8k_modular_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="modd-20230515.xsd" xlink:type="simple"/>
    <context id="From2023-05-15to2023-05-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-05-15to2023-05-15">0001074871</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-05-15to2023-05-15">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2023-05-15to2023-05-15">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-05-15to2023-05-15">2023-05-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-05-15to2023-05-15">MODULAR MEDICAL, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-05-15to2023-05-15">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-05-15to2023-05-15">001-41277</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-05-15to2023-05-15">87-0620495</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-05-15to2023-05-15">10740 Thornmint Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2023-05-15to2023-05-15">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-05-15to2023-05-15">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-05-15to2023-05-15">92127</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-05-15to2023-05-15">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-05-15to2023-05-15">800-3500</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2023-05-15to2023-05-15">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-05-15to2023-05-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-05-15to2023-05-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-05-15to2023-05-15">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-05-15to2023-05-15">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-05-15to2023-05-15">MODD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-05-15to2023-05-15">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-05-15to2023-05-15">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( +.*L58'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "SBK%6#?!R6.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)OIW]0(71S43PI""XHWL)D=C?8M"$9:??M3>-N%]$'$'+)S"_?
M? /IT$L< SV'T5-@2_%J=OT0)?J-.#!["1#Q0$[',B6&U-R-P6E.U[ 'K_%#
M[PF:JKH!1ZR-9@T+L/ K4:C.H,1 FL=PPAM<\?XS]!EF$*@G1P-'J,L:A%HF
M^N/<=W !+#"FX.)W@<Q*S-4_L;D#XI2<HUU3TS254YMS:8<:WIX>7_*ZA1TB
MZP$IO8I6\M'31IPGO[9W]]L'H9JJ:8OJNJAOMTTMTVG;]\7UA]]%V(W&[NP_
M-CX+J@Y^_0OU!5!+ P04    " "SBK%6F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M +.*L580CW&H-@0  &$0   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MG9AM;^HV%,>_BI5)TR:5YJ$\M0,D"NT=NGU@A7NOM&DO3&+ :F)GME/@V^\X
M0,+N#2=H;TJ<Y/SSR_')_]CM;:1ZUVO&#-DFL=!]9VU,>N>Z.ERSA.IKF3(!
M5Y92)=3 4*U<G2I&HSPHB=W \]IN0KEP!KW\W%0->C(S,1=LJHC.DH2JW3V+
MY:;O^,[QQ!M?K8T]X0YZ*5VQ&3-?TJF"D5NH1#QA0G,IB&++OC/T[^Z#I@W(
M[_C*V4:?'!/[*@LIW^U@$O4=SQ*QF(7&2E#X^6 C%L=6"3C^.8@ZQ3-MX.GQ
M4?TQ?WEXF075;"3C;SPRZ[[3=4C$EC2+S9O<_,X.+]2R>J&,=?Z7;/;W-IL.
M"3-M9'((!H*$B_TOW1X2<1(0!&<"@D- D'/O'Y13CJFA@YZ2&Z+LW:!F#_)7
MS:,!C@L[*S.CX"J'.#,8R0^F>JX!*7O"#0]A]_NPX$S8,]T1OW5% B^X^6^T
M"P %15!0!+G<#49!_AHNM%$P3W]7 >T5FM4*MGCO=$I#UG>@.C53'\P9_/R3
MW_9^0_AN"KX;3'TPEF$&I6C(?)>R*C@\O-OXC$ T"X@FJC($@BBG>(SIJHH"
MCU_26#.$HU5PM"Y+QI0I+B/R("("M5>9%USI6$5U9=0NR-JHWH,PW.S((X\9
M><F2175EXQJ>YS>:?M#I(#R=@J=S"<\;6W%;V)"R%YI4Y@G7>7X=?WD:OI'G
MA_%D-'RZ(I.7T37"URWXNI?PC6 R%8W)1$1L2SZS714AKN1!VKQ.L]OQ$:S;
M NOV$JPYW9))!&Q\R4.:>_CY2<45NYV&UPZ\YFT+P?.]TC.]2P G(I0JE2IG
MNR(S Q\!D8J,9 8)A;S*J'*R:]1?OF*0)\;N7P(YC"+P0WUU/"!/<!]Y%=5D
MN*2=8H_,UU():$6&O$D:8:RE_?NH>__ .K(CR.1<;D0E)RXWHX*,.5M)#*[T
M?A]W[^_ABGF>*OG!15B=25QS-,30RH[@XY;^/=I4:@,?\I\\/5]\N.)M -Z'
ML95=PL?-/9_#(:P4SZ/@ MU6%P,IFX*/._J3#"$GT[446%>H$>EZ7N.FY7D8
M4=D6?-S/OREN#!.0F"3)Q,'<="45+E37TOVR$_BX@<]DS$-NN%B19RAOQ6E<
MR8.KU/*4+<#''7NJ6".$]##XOO8K+UC\P!KQ=;D\,W^X7AU94)I_@-OS#V03
MK3,@JP.LD:T%+(T_P%UZS@VL?^22^,$OBU_)C(49U%ME4Z]1LO4)77=F9/B.
MH9TL\W%CGBL:V1*;[9*%K"RP&@%8"8TQDM+4 ]R CUDA#]MP3<6*G5V:U0B]
M#&?CX1\84^GFP45N_I PM;)9^@0*9FU=(J6B>O[^YXK?/=DPVLWW,[5/U"1F
M2Q#RKCO@S&J_G]T/C$SS/>1"&MB1YH=K1J'>[0UP?2FE.0[LMK3XK\+@7U!+
M P04    " "SBK%6GZ ;\+$"  #B#   #0   'AL+W-T>6QE<RYX;6S=5VUK
MVS 0_BM"/V!N8FKBD1BV0&&PC4+S85^56'8$>O%DN7/ZZZ>S;"=I=67=A['-
MH<G=/;J[1W<GF:Y;=Y+\X<BY([V2NMW0HW/-^R1I#T>N6/O.-%Q[I#)6,>=5
M6R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0G
MCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K <XRBAC05C$C*$
M[_VX_!DP::U7A90SP24-AF+=,.>XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,
M/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!
M6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@
M?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\
M@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T
M7!S1JP,Z6PE<A!OZ%>Y7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIU
MTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD<VWL,\E=,E[7FY'U=;[021>\%G'
M!QR>(W?#$T<PGX#%$<"P/!@#S"=X87G^I_VLT/T$#..VBB(KU&>%^@2O&+(=
M/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@
M/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&
MD3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?
M)=-[*CG_5U/\!%!+ P04    " "SBK%6EXJ[',     3 @  "P   %]R96QS
M+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0
M"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#
ML%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S
M##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H
M5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( +.*L5:JQ"(6,P$  "("   /
M    >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P%K0A#5%>0-N0I@V-B??0
MNM0BB2O'A8VOG]NJ&M)>]I3<V;K<7187XM.!Z)1\>1=B;FJ19IZFL:C!VWA'
M#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6VG-X"$B@$*2C9$7N$2_R=
M=S Y8\0#.I3OW/1W!R;Q&-#C%<K<9":)-5U>B/%*0:S;%4S.Y68R#/; @L4?
M>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z0B? :ROPS-0V&(Z=
MC*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&))@G60VY6= ;N\N@#
MFW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG5LJ]
MAU>RY1AQ_)[E#U!+ P04    " "SBK%6)!Z;HJT   #X 0  &@   'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,75@K+A %
M\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO *1;M(HN
MSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR./ /,+Q=
MZ*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W
M]T6NS>,)KM\,<'AT_@%02P,$%     @ LXJQ5F60>9(9 0  SP,  !,   !;
M0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:
MJ_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)X
MKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G 8ED\
MC<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)
M7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\
MP68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B
M6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " "SBK%6
M!T%-8H$   "Q    $               @ $     9&]C4')O<',O87!P+GAM
M;%!+ 0(4 Q0    ( +.*L58-\')8[@   "L"   1              "  :\
M  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( +.*L5:97)PC$ 8  )PG
M   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#
M%     @ LXJQ5A"/<:@V!   81   !@              ("!#0@  'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( +.*L5:?H!OPL0(  .(,
M   -              "  7D,  !X;"]S='EL97,N>&UL4$L! A0#%     @
MLXJQ5I>*NQS     $P(   L              ( !50\  %]R96QS+RYR96QS
M4$L! A0#%     @ LXJQ5JK$(A8S 0  (@(   \              ( !/A
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( +.*L58D'INBK0   /@!   :
M              "  9X1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( +.*L59ED'F2&0$  ,\#   3              "  8,2  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  ,T3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea178793-8k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modular-medical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ea178793-8k_modular.htm">ea178793-8k_modular.htm</File>
    <File>ea178793ex1-1_modular.htm</File>
    <File>ea178793ex5-1_modular.htm</File>
    <File>ea178793ex99-1_modular.htm</File>
    <File>modd-20230515.xsd</File>
    <File>modd-20230515_lab.xml</File>
    <File>modd-20230515_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea178793-8k_modular.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ea178793-8k_modular.htm"
     ]
    },
    "labelLink": {
     "local": [
      "modd-20230515_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "modd-20230515_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "modd-20230515.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "MODD",
   "nsuri": "http://modular-medical.com/20230515",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea178793-8k_modular.htm",
      "contextRef": "From2023-05-15to2023-05-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://modular-medical.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea178793-8k_modular.htm",
      "contextRef": "From2023-05-15to2023-05-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://modular-medical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001213900-23-040917-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-23-040917-xbrl.zip
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M.M2*CISJTH%A@K9^8FS1UC7^81(4&"F#0\$/1T <M4O-H<E2E[0GS&?4-$@
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MIC&(FB,V)VIA2]\F=I=X?1:J"J8-N>$9,'E]I/6I!5J[HGG82BWG\K\T0=^
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M.WM,JY&XM[\W^\N5:RW</OLI"[*VCL!W9GQS0^X/<>%+,TZH= 1 -W:)K%8
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M:W/;2+(F_)T1_ ]X)W8GI A8;4EVM[O=ZPCYUJ/W=-M>7V;.^0@2H(0V"7
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ME[('2[+; +:"BDS02/K 2>&3NE$)X_3R6:[#-KQ4M_G&_MJ7]?$!7JT2!V4
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M%9E0529(0UA>VJ<G-+\F*P@-LRH08PX/,E.44C!\)NZC21/(JNZE^WN/]F&
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MKF$VAI%TP2U68Q!\)69'P3\P>"@83"1G!@^)?EXL24$Z$#99QE<O/3:JDIR
M:(:F?F:*/)1;GA=-5<*EJ$ZQ^:O!UER>E_0H(=XW[7?,4_UO<:D(K1:'91?9
M8H()!5.9P+@6&2&W$J TK7'C>]89#DD^SRT8(*GK<BH_VAHD_4*V!,4W:-1F
M+VBS.99J WLM'FE-VZ_U6B ,B*WHS(JX!J!^NM9"W4W,]NZX]AQ7BP;XP ZE
M1,5LN8'KA5MDC8E=6<5L0^*&*(<H<5H5=M*P0E%:PA>TY)#8(?&E$;G, Q.9
M<F_NH.7( (0*_:^WLP.RGX?W[]*?-OUY>/\[R7]^A[(\3$L]L"8VJ8T3=S5U
M0_>AD'6WN(7C&H35H,@:?N3P_O]FV)M+#8&Q7O?557K<%7BO(F_$^MX\+SXB
M@:[[&[O[U._4:CA]I6:IL1_(C/=4HZ\UY79UF4C/.&7_.4"3UMM\C%ZUWQ_3
M4*:TT\W1GKKH%UE22-T8/<PMSC,)"[R%ET</#X\.]V;[8(KMRZZ84*+]B:J\
MRCFWAI4?YM+ @F-3?--/F>E,/B' *OX +G![3<>CGN&>X,+"T YCU\ET+\ML
M(].GZWN_2VB8ETE076M[:\D?-N_17_!^&G:F'Q[8L*5-KBI&=)5QM>9>R["
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MZ:XW-ZHE_=@%)W15/R(E:MTZ] 9HF\!8J;+M,(5>5DZ>5*"F('27G2=U#_$
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M!FSE85''$;5KJ-;&=%ID&;%Y&:'40.F)">FX$CG7J)'GP1^9&AC0/IMQ%!Y
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ML'#\[<_OSK/LYBY.Q@AC8V5Y'TCVF0FA&DU619NE'3N6\6K[Q?G^G(:7Z!_
M(.=E03$CMJ/-D^+HM)@>$.1WXXBP!G1*D!Y_##8^JJWTVUU(]K5E]-B347)E
M;MB8$RT?PGA9[I2VM^[#+(UU1H$ NA+A'K >E@99+"M*@\G$-M X=.XM0]L0
MN*@4)3CC4+F<\B)7D32,/A@FFH2BY'$$;N>91-3R!=BOE69]!\5_4<XOC"LI
M"W!;U>O7K7P\.KS+_[O\_^%WDO__#F5YD 9^H/SI9&TBAR]8XX5P?@Q_,S4G
MH.3 PI8PDZY)=X#3C07K/CH)]!;8X4F>&AX/_TM,9,,CPTH"LJC-(^"2(-M5
MJBPHM0^:]BSQNFNT?2/_NK !-;@+3!07<85<!O,+Y=\=JQLV=1. L><KV2&V
M 7>A>LVK PV$EZ:<VT(,2U;7B@S*#NC 8,"49[A :'KL$-II[>D*FO-,AS'M
M5]*\GH )[XIR-C@L^ZZ%:L!U&4:.Z'":H1>U4LB4-G;>\3RY=/$:G4:N0QYE
MFJ$GR%TV$08Q+6OQ<,T"4=PA41TR*ION\'8)CM'+TU=O3Y3<!9=_\!J;UAL!
MQ*@GBV+&X*!@#JF>@PY)A\08[ 0P0J@9$Q6EF=-5!6OH;-U7CTMJED*?/ MM
MI8,GF7M*2M(@RYE479GT^WE9F]ZF^"GLGUH563N%[$Z0*_#34["H#K4 <%(O
M,J5QPD^,I+N6R(!TUW*XT=;A,<!5&S1 BDR[I4'M9G, E6H UTH,[*1&O'/3
M3A'0@9>V/SSVFKRD[)/)<K?"DH$7P:C/F (RS1#*DQ<(1IIQ+@PG&[>$EPM!
MMBSTU+9:XMQ;XH=2DQ1L8&R7M%78]OY?>U_^VS:2K?N[ ?\/1&/FP@*8M+=T
M)^V^#3A+SWA>MI>D7]Y@,'B@),IF1R(U)&5']Z]_=;:J4V21DKS%27POT!/;
M$EG+J5-G_;[3@;?25O=09([TOS'>*;W'1XV!](2#:47%N:Y+5J?;KR,FRJA6
M(?$@V(>!P<*B# Q\0L>11QYU#USAU'=T:M*U(H>\(M:UPC*EV3^8]=DY&S2U
M4F!76Z<G)(YV8ZE--@WH5,9U)2DGA01Z!U*OQE?"$NI 0$ZL#/^YB$;:L5P4
MDX(?O:8AVX3K)]L:YZV5# @<.#.8/T,'7E*^$E%(O(B"K3&ZJM5@7O]IP"?:
MO2L?_PC78IW,YE&=?$X5W9,Q[W!_%W-6%/9;<&.J>U45$*%:"#K8.]-!P^1+
MYN"\MH/7&O-<B415%:-,D3\#I/.(C42D]JRS2JE%>]>RA43 Q1#Z22E,;1?^
M(]R\[VMS+.KH'\6BS)D7&(SR?Q;E)S')=V8#EG6[=>V[6-^80^/6G99&PHV9
M>):.6O1T;I>\B\2QOZU09T=1H[T^AE]8H*\_--#7+/F<S18SA<U$4PG9,%:]
M!'J_F_F2:C$TQ\GX!,G\#".UQE#FZBXS\],S_-6,?L7,J&M<^#BV[:U^G=+;
MK]B!<-;(28$'H_R!1J#Y$$>M ""@K\)\\2][^X_BW=U=<H^:.0>S%PNS-O94
M@$7"-8952SCEC#4)U0)>%1E:%KG+]X_H6/':5"FJ#[-17%%&_@)Z5XVSUCZJ
M=S7R<X>3_$\\2ALJQ1:7Y;79B[>\^UT5(@!HL&S+BI4@*RT6$1MKI8EYE('!
MH2D-ZI3R6D&8)VHL-7<2N=),YP:-$I(I-N+_H(8V&;; 75RJN-)Y9PH&^*Y7
M.MQA6=O3K*C/E6WP(D%(_4I5TS$X/[&R_YV2METRB.4-KI+ Z\U4M0-+6V"0
M !(U%+,C527$DK'_@#H(,7J24(@^(;$Q]EI51^/$&C*3;%*G9IAGT<[>HU_?
M__'VM_KLUQ_A?P?4&S ROGH^3DIJ=U"0&CUA?Q WP$ZDI7!9\AU*MN:@OF%P
M1AVRE2<4X1L6_3&R4#?0,Z;;U\%HA?5BU [*-IL_5-SH8*/[#MUD[]%CB$7Y
MY 9[>_"[8#_F $ ]V+#5^115"Y9.H;YR;W] K:VC!5K\W&0BF"<K$B[W9_H*
M9UKSPYKC"^35_Z-PYUZG62VD"G)J<VC6Y;.IR+^9P@,+7B4>$2N+DN A'%GP
MCD9QX\9FBS>LK()!3-!#1DOD#F,"?I2G3XD&-I>?F'.-Y),B9V1S25$]@?T(
MH-78_GZ&Y>BZ)J+!NTV5N]C@P 3<L4!/N1J,5W(:=/E0;&M< $XK!OW@UIJ*
MO/)L+H_@!U J3]INK!YL1)6AP"D9 >LX]46EW%.&H^SM+FMC.P1\QSMWO%8D
MRO;O$V4N4;;_C23*[G5XCP[7+,T4B4ZF$5")E$6(X7NC[E=;%YY(>17H>'F)
M,DU&_#[CED-$(4N9WE)*'S1(<V7,=.KR,=9.4MJ4$=($@5HD)>>J6*GZ0>)E
MI!HAEF:U9;#@E0*7--3M+0N* 9,903 ?LW8855#6)Q;A0)FDFQH$ZT;9?)I*
M32&BB4'DU#POFAMM,))@&'I0XT7)R'B_&-MF )8/E=9SA@37-,TE:4B9!8'2
MR_5*C:&6"9=Y4;H^4ZA0Q V;3!EC3E=5V-"0F:T?;3+KGM:M9, 1UK;T;1-'
M-+Q7(#[=B.A.D@8Y$[/#K+-%T+MVV<U0 'Y<4:@"->.LQEUH%FN64 <(S\&F
MO2*?+GUY .@A:(Y>F,TM^7K&IYB#;O23[<55=HWK<@5MCH6I!RL6U(F]3\G$
MT("0OQC5TJ^[R&4TN!+&ZJ=]C2,V1M1>=V4Q>.MQL48(C((ED0K&CNG#"G&9
MVIMUYPR!KTE''^@XC<LD=6EG*6+<T#?$JJX5#$"6YJF'DL@&3N@M,K9C]S8
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MR$B&V=O,.[$BD@#.AT0DKG$IK/%>E)>!G_UN.;/@I"H;4!W.'ASD&SFAD7=
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MH^2*0,RH^\:B(5.%,S\1T)V,KI@6<XN=&H.&@7+,4EK6*6MT>@J$*;"NA,M
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M:7Y36NX-"4C4*+>W[ X:E?4V*=&E6'F(8H8W4\TG>6,4>BF:[UBNCY_FJBA
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M?&JEQ1^31'*JD@6#<.5A*/%ZZ5<1-"FYI[ X0^%5#G0EJ2S:/[[60P_KNN2
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M.HXL!95+$V',P2AR!TPRSB98Q,3W$1QGU^Z V@!:!ER>J5/O2;2/MS.@;\Y
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MA/6!'*R*2O9LDR@"04U3MBLP)1F\7C=C" \K6\:K 3GT"PS5#>*9'2S"D1"
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MY8,$7(0<103OV*A,RRS>EU3^ EL#%-YA0U0;+LC6\,,=@1<5?Y^1;1(F9.A
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M[ 1<Z',,J8";%>4+CGP#1&F-C K$%P#?Y 2,2]61W]LL9*!T"KNKF E2=S1
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M:*,WS_^)&$=___#JI?G'_P=02P,$%     @ LXJQ5J/F8G(;#   *3<  !D
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MW'SY>GQ-P <F'G"F@0L_[E8W6H)]!5LM!?>53DECMTJ:3K.51;.:UZS[#1@
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M9_;VVDEG;W\CYU*-6F/T%U QUXX*$H @*=T7359AV3,#\ _NX]_1@I='1F;
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M<8KR,F'\ %TB2I14-('(;+DJ M2G1HZJW'MX4XRH-"8C#NNKJ'K-K]65"G6
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M=*J7HGH%:*6>$2NK0+^I2E!>B^WWR^N;KN4GN5EODG^M<$KDEO\"4$L#!!0
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M-!3(-RE54SNH?51R86;KO9TAV)X"4.B(*UN#4G'@+W_N(R_VOP7)5UB#WTZ
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M.3,M.&M?;6]D=6QA<BYH=&U02P$"% ,4    " "SBK%6S9S$ZDK(  # 9 0
M&0              @ '+&0  96$Q-S@W.3-E>#$M,5]M;V1U;&%R+FAT;5!+
M 0(4 Q0    ( +.*L5:CYF)R&PP  "DW   9              "  4SB  !E
M83$W.#<Y,V5X-2TQ7VUO9'5L87(N:'1M4$L! A0#%     @ LXJQ5J4-C.0B
M"P  X"4  !H              ( !GNX  &5A,3<X-SDS97@Y.2TQ7VUO9'5L
M87(N:'1M4$L! A0#%     @ LXJQ5@-^B$XO P  P L  !$
M ( !^/D  &UO9&0M,C R,S U,34N>'-D4$L! A0#%     @ LXJQ5BT:84O^
M"@  @(8  !4              ( !5OT  &UO9&0M,C R,S U,35?;&%B+GAM
M;%!+ 0(4 Q0    ( +.*L5:BY8EY6P<  .-7   5              "  8<(
M 0!M;V1D+3(P,C,P-3$U7W!R92YX;6Q02P4&      < !P#@ 0  %1 !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
